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Summary of findings {#CD001261-sec1-0001}
===================

Summary of findings for the main comparisonTy21a vaccine (three doses) versus control for preventing typhoid fever**Ty21a vaccination (three doses) versus placebo for typhoid feverPatient or population**: adults and children aged 5 years of age and older\
**Settings**: any\
**Intervention**: oral Ty21a (3 doses) ‐ liquid, enteric capsule, or gelatin capsule\
**Comparison**: placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboTy21a (3 doses)Cases of typhoid fever,**\
**Year 1Medium‐risk populationRR 0.55** (0.35 to 0.86)76,296 (3 studies)⊕⊕⊕⊝ **Moderate**^a,b,c,d^\
Due to imprecisionCases of typhoid fever are probably reduced with vaccination**4 per 10,0002 per 10,000** (1 to 3)**High‐risk population59 per 10,00032 per 10,000** (21 to 51)**Cases of typhoid fever,**\
**Year 2Medium‐risk populationRR 0.41** (0.29 to 0.57)76,296 (3 studies)⊕⊕⊕⊝ **Moderate**^a,b,d,e^\
Due to imprecisionCases of typhoid fever are probably reduced with vaccination**4 per 10,0002 per 10,000** (1 to 2)**High‐risk population59 per 10,00024 per 10,000** (17 to 34)**Cases of typhoid fever,**\
**Year 3Medium‐risk populationRR 0.44** (0.25 to 0.76)76,296 (3 studies)⊕⊕⊕⊝ **Moderate**^a,b,d,e^\
Due to imprecisionCases of typhoid fever are probably reduced with vaccination**4 per 10,0002 per 10,000** (1 to 3)**High‐risk population59 per 10,00026 per 10,000** (15 to 45)**Cumulative cases of typhoid fever at 2.5 to 3 yearsMedium‐risk populationRR 0.50** (0.39 to 0.65)235,239 (4 studies)⊕⊕⊕⊝ **Moderate**^a,b,d,f^\
Due to imprecisionCases of typhoid fever are probably reduced with vaccination**4 per 10,0002 per 10,000** (2 to 3)**High‐ risk population59 per 10,00030 per 10,000** (23 to 38)\*The incidence of typhoid in a medium ‐risk setting is taken from the control group in a study from China ([@CD001261-bbs2-0025]).The incidence of typhoid in a high‐risk setting is taken from a study in India ([@CD001261-bbs2-0021]). This is consistent with the incidence levels described by a global epidemiological study ([@CD001261-bbs2-0091]). **Abbreviations: CI**: confidence interval; **RR**: risk ratio.GRADE Working Group grades of evidence **High certainty**: further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty**: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty**: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty**: we are very uncertain about the estimate.[^2]

Summary of findings 2Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever**Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid feverPatient or population**: adults and children of 2 years of age and older **Settings**: any **Intervention**: Vi polysaccharide vaccine (1 dose) **Comparison**: control; efficacy**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskControl; efficacyVi polysaccharide vaccine (1 dose)Incidence of typhoid fever** -- **year 1** Blood culture**Moderate**^a^**RR 0.31** (0.26 to 0.37)99,797 (3 studies)⊕⊕⊕⊕ **High**^b,c,d,e^Reduces incidence of typhoid fever**4 per 10,0001.2 per 10,000** (1.0 to 1.5)**High**^a^**59 per 10,00018.29 per 10,000** (15.34 to 21.83)**Incidence of typhoid fever** -- **year 2Moderate**^a^**RR 0.41** (0.31 to 0.55)194,969 (4 studies)⊕⊕⊕⊝ **Moderate**^b,f,g,e^\
Due to inconsistencyProbably reduces incidence of typhoid fever**4 per 10,0001.6 per 10,000** (1.2 to 2.2)**High**^a^**59 per 10,00024.19 per 10,000** (18.29 to 32.45)I**ncidence of typhoid fever** --**year 3Moderate**^a^**RR 0.5**\
(0.32 to 0.78)11,384\
(1 study)⊕⊕⊝⊝\
**Low**^h,i^\
Due to imprecision and indirectnessMay reduce incidence of typhoid fever**4 per 10,0002 per 10,000**\
(1.28 to 3.12)**High**^a^**59 per 10,00029.5 per 10,000**\
(18.88 to 46.02)**Cumulative cases of typhoid fever at 2.5 to 3 yearsModerate**^a^**RR 0.45** (0.30 to 0.70)11,384\
(1 study)⊕⊕⊝⊝\
**Low**^h,i^\
Due to imprecision and indirectnessMay reduce incidence of typhoid fever**4 per 10,0001.8 per 10,000**\
(1.2 to 2.8)**High**^a^**59 per 10,00026.55 per 10,000** (17.7 to 41.3)**Serious adverse events**No serious adverse events reported**Fever5 per 10005 per 1000**\
(4.2 to 5.7)**RR 0.98** (0.84 to 1.13)132,261 (3 studies)⊕⊕⊕⊝ **Moderate**^b,c,k,l^\
Due to imprecisionProbably little or no association with fever**Erythema5 per 10006 per 1000** (2 to 22)**RR 1.15** (0.33 to 4.03)132,261 (3 studies)⊕⊕⊕⊝ **Low**^b,j,l^\
Due to imprecision and inconsistencyMay have little or no association with erythema\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: CI**: confidence interval; **RR**: risk ratio.GRADE Working Group grades of evidence: **High certainty**: further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty**: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty**: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty**: we are very uncertain about the estimate.[^3]

Summary of findings 3Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever**Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid feverPatient or population**: adults and children of 2 years of age and older **Settings**: any **Intervention**: Vi‐rEPA vaccine (2 doses) **Comparison**: control; efficacy**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskControl; efficacyVi‐rEPA vaccine (2 doses)Incidence of typhoid fever** -- **year 1** Follow‐up: 1 year**Moderate**^a^**RR 0.06** (0.01 to 0.25)12,008 (1 study)⊕⊕⊕⊝ **Moderate**^b,c^\
Due to indirectnessProbably reduces incidence of typhoid fever**4 per 10,0000.24 per 10,000** (0.04 to 1)**High**^a^**59 per 10,0003.5 per 10,000** (0.6 to 14.8)**Incidence of typhoid fever** -- **year 2Moderate**^a^**RR 0.13** (0.04 to 0.44)12,008 (1 study)⊕⊕⊕⊝ **Moderate**^c^\
Due to indirectnessProbably reduces incidence of typhoid fever**4 per 10,0000.52 per 10,000** (0.16 to 1.8)**High**^a^**59 per 10,0007.7 per 10,000** (2.4 to 26.0)**Cumulative cases of typhoid fever at 2 yearsModerate**^a^**RR 0.09** (0.04 to 0.22)12,008\
(1 study)⊕⊕⊕⊝ **Moderate**^c^\
Due to indirectnessProbably reduces incidence of typhoid fever**4 per 10,0000.36 per 10,000** (0.16 to 0.88)**High**^b^**59 per 10,0005.31 per 10,000** (2.36 to 12.98)**Cumulative cases of typhoid fever at 3.8 yearsModerate**^a^**RR 0.11** (0.05 to 0.23)12,008\
(1 study)⊕⊕⊕⊝ **Moderate**^c^\
Due to indirectnessProbably reduces incidence of typhoid fever**4 per 10,0000.44 per 10,000** (0.2 to 0.92)**High**^b^**59 per 10,0006.49 per 10,000**\
(2.95 to 13.57)**Serious adverse events**See commentSee commentNot estimable12,008 (1 study)See commentNo serious adverse events were reported**Fever after Vi‐rEPA (dose1)5 per 100013 per 1000**\
(8 to 18)**RR 2.54** (1.69 to 3.62)12,008 (1 study)⊕⊕⊕⊝ **Moderate**^d^\
Due to imprecisionProbably associated with fever following vaccination**Fever after Vi‐rEPA (dose2)4 per 100018 per 1000**\
(11 to 27)**RR 4.39**\
(2.85 to 6.77)11,091\
(1 study)⊕⊕⊕⊝ **Moderate**^d^\
Due to imprecisionProbably associated with fever following vaccination**Erythema after Vi‐rEPA (dose 2)0.2 per 10000.4 per 1000**\
(0.04 to 4.4)**RR 2.01** (0.19 to 22.21)11,091 (1 study)⊕⊕⊝⊝ **Low**^d,e^\
Due to serious imprecisionMay have little or no association with erythema**Swelling at injection site after Vi‐rEPA (dose 2)0.2 per 10004 per 1000**\
(0.5 to 30)**RR 20.15** (2.71 to 150.08)11,091 (1 study)⊕⊕⊕⊝ **Moderate**^d^\
Due to imprecisionProbably associated with swelling at injection site\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: CI**: confidence interval; **RR**: risk ratio.GRADE Working Group grades of evidence: **High certainty**: further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty**: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty**: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty**: we are very uncertain about the estimate.[^4]

Summary of findings 4Vi‐TT conjugate vaccine (PedaTyph) (2 doses) versus control for preventing typhoid fever**Vi‐TT conjugate vaccine versus control for preventing typhoid feverPatient or population**: children aged 6 months to 12 years\
**Settings**: India **Intervention**: Vi‐TT (PedaTyph) vaccine (2 doses)\
**Comparison**: control; efficacy**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed risk^a^Corresponding riskControl; efficacyVi‐TT conjugate; (2 doses)**Incidence of typhoid fever -- year 1\
Follow‐up: 1 year13 per 10000.8 per 1000\
(0 to 13)RR 0.06^b^\
(0.00 to 1.01)1625 (1 study)⊕⊝⊝⊝ Very low^c,d,e^\
Due to risk of bias, serious imprecision and indirectnessWe do not know if this vaccine prevents typhoid fever\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: CI**: confidence interval; **RR**: risk ratio.GRADE Working Group grades of evidence **High certainty**: further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty**: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty**: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty**: we are very uncertain about the estimate.[^5]

Background {#CD001261-sec1-0002}
==========

Description of the condition {#CD001261-sec2-0001}
----------------------------

### Epidemiology {#CD001261-sec3-0001}

Typhoid fever is a systemic infection caused by the Gram‐negative bacterium *Salmonella enterica* serovar Typhi (*S.* Typhi). *S.* Typhi spreads by food, drink, or water contaminated by faecal or urinary carriers excreting the bacteria. Typhoid fever, also called enteric fever, remains an important global public health problem. Estimating disease burden is difficult for a number of reasons, including the poor sensitivity of diagnostic tests and lack of surveillance in countries with suspected high prevalence ([@CD001261-bbs2-0086]). In 2010 there were an estimated 20.6 million cases of typhoid fever in low‐ and middle‐income countries, with 223,000 deaths (although after adjusting for risk factors and corrected diagnostic testing, the estimate dropped to 11.9 million cases and 129,000 deaths; [@CD001261-bbs2-0105]). This lack of robust data makes decision‐making on priorities and resource allocation difficult and may negatively impact investment in typhoid fever ([@CD001261-bbs2-0092]).

The highest burden of typhoid fever is thought to be in South Asia ([@CD001261-bbs2-0116]). Typhoid fever incidence in sub‐Saharan Africa has historically been poorly described; but the recent Typhoid Surveillance in Africa programme, funded by the Gates Foundation, has shown that incidence in many African countries may be as high as that in Asia ([@CD001261-bbs2-0114]). Typhoid fever is rare in industrialized nations, although travellers to endemic countries are at risk of acquiring the disease, with a recent survey naming it the second most common potentially life threatening infectious disease in travellers ([@CD001261-bbs2-0098]).

Until recently, the common view was that typhoid fever mainly affects children of school age and adults. However, experts now recognize that typhoid fever is an important cause of morbidity among younger children in areas of high incidence ([@CD001261-bbs2-0107]; [@CD001261-bbs2-0111]; [@CD001261-bbs2-0113]).

### Clinical features {#CD001261-sec3-0002}

After ingestion of *S.* Typhi or *S.* Paratyphi, the bacteria spread from the intestine via the blood, where they multiply to the intestinal lymph nodes, liver, and spleen. Typhoid fever is usually characterized initially by fever, headache, and abdominal symptoms, although other nonspecific symptoms may occur. Neuropsychiatric manifestations, including psychosis and confusion, may occur. Other signs include relative bradycardia, rose spots, hepatomegaly, and splenomegaly, although these signs are not pathognomonic ([@CD001261-bbs2-0103]).

Complications occur in 10% to 15% of untreated patients, usually in the third and fourth weeks of infection. The most important complications are gastrointestinal bleeding, occurring in up to 10% of patients ([@CD001261-bbs2-0108]), followed by intestinal perforation and typhoid encephalopathy. Estimates of case‐fatality rates in typhoid fever range from 1% to 4%; fatality rates in children younger than 4 years of age are 10 times higher than in older children. In untreated cases, the fatality rates may rise to 10% to 20% ([@CD001261-bbs2-0088]).

Both *S.* Typhi and *S.* Paratyphi can cause enteric fever, and the clinical manifestations of these two infections are similar. In some areas enteric fever caused by *S.* Paratyphi is more common ([@CD001261-bbs2-0102]).

### Diagnosis and treatment {#CD001261-sec3-0003}

Confirmation of typhoid fever requires isolating *S.* Typhi from blood, bone marrow, stool, or duodenal fluid by culture. The Widal test, which identifies antibodies against *S.* Typhi antigens in blood, has poor sensitivity overall and poor specificity in endemic areas ([@CD001261-bbs2-0087]; [@CD001261-bbs2-0109]). New‐generation, rapid, serologic tests have been developed, including a dot enzyme‐linked immunosorbent assay test that detects IgM and IgG antibodies against an outer membrane protein of Salmonella Typhi (Typhidot) and an anti‐O9 IgM antibody specific for group D Salmonellae (Tubex) ([@CD001261-bbs2-0101]). However, a recent systemic review found inadequate sensitivity and specificity for these as well ([@CD001261-bbs2-0115]).

Effective and early treatment with antibiotics shortens disease course and reduces the risk of complications ([@CD001261-bbs2-0100]). A multi‐drug resistant (MDR) strain of *S.* Typhi to chloramphenicol, ampicillin and co‐trimoxazole emerged in the late 1980s in Asia, and later in Africa. This has declined with widespread use of fluoroquinolones. Unfortunatley, *S.* Typhi strains with reduced sensitivity and resistance to fluoroquinolones developed in the 1990s, mainly in the Indian subcontinent ([@CD001261-bbs2-0116]). Third generation cephalosporins (such as ceftriaxone and cefotaxime) are often used, particularly in patients admitted to hospital. Sporadic reports of emerging resistance to these antibiotics is of serious concern ([@CD001261-bbs2-0100]). Azithromicyn is being used increasingly as a first‐line oral treatment option.

### Potential control measures {#CD001261-sec3-0004}

Given the route of transmission and the fact that humans are the only source of infection, improved sanitation and food hygiene are important control measures. However, these measures are associated with socioeconomic progress, which has been slow in most endemic areas. Furthermore, achieving control of typhoid fever by antimicrobial treatment alone requires well‐functioning medical services and is hindered by the increasing problem of antibiotic‐resistant *S.* Typhi*.* Therefore vaccination against typhoid fever is a key control measure in high‐risk areas ([@CD001261-bbs2-0119]). In addition to the populations residing in areas in which typhoid fever is endemic, travellers to these regions as well as household contacts of typhoid fever carriers and laboratory workers may benefit from an effective vaccine ([@CD001261-bbs2-0108]).

Description of the intervention {#CD001261-sec2-0002}
-------------------------------

Vaccination against typhoid fever is a key control measure; however, despite their evaluation in populations in endemic low‐ and middle‐ income countries, travellers from high‐income countries are the primary users of typhoid fever vaccines. This situation is changing, thanks to the availability of high‐quality burden of disease data from endemic countries ([@CD001261-bbs2-0107]); to the experience of typhoid vaccination programmes in Thailand, China, Vietnam, and India ([@CD001261-bbs2-0094]); and to vaccine demonstration projects in five Asian countries ([@CD001261-bbs2-0106]). A 2008 World Health Organization (WHO) position paper on the use of typhoid vaccines concluded that given the continued high burden of disease and increasing antibiotic resistance, countries should consider the programmatic use of typhoid vaccines for controlling endemic disease ([@CD001261-bbs2-0119]). Despite this recommendation, very few typhoid endemic countries have implemented a typhoid vaccination programme ([@CD001261-bbs2-0104]). Up until recently, there were no typhoid vaccines effective for children younger than two years, who carry a large disease burden in developing countries. More recently, newer typhoid conjugate vaccines (TCV) have entered use, with evidence of immunogenicity in children from six months old. These show a potential for inclusion in the infant expanded programme on immunization ([@CD001261-bbs2-0093]).

The following typhoid vaccines have been developed.

### Inactivated whole‐cell typhoid vaccine {#CD001261-sec3-0005}

Although vaccines of this type were introduced in 1896 ([@CD001261-bbs2-0118]), their efficacy was established only in 1960 in controlled trials in Yugoslavia, the Soviet Union, Poland, and Guyana. The 1998 version of this Cochrane Review demonstrated that two doses of this type of vaccine resulted in 73% efficacy over three years (95% confidence interval (CI) 65% to 80%) ([@CD001261-bbs2-0124]). Different methods of inactivating *S.* Typhi cells have been used to prepare these vaccines: acetone‐inactivated, alcohol‐inactivated or heat‐inactivated and phenol preserved. In field trials, the vaccine has been associated with fever and systemic reactions in 9% to 34% of recipients, and with short absences from work or school in 2% to 17% of cases ([@CD001261-bbs2-0117]). Therefore, the inactivated whole‐cell typhoid vaccine is considered unsuitable for use as a public health vaccine, and, although licensed, it is no longer available for use ([@CD001261-bbs2-0095]). Consequently, we have not included killed whole‐cell vaccines in this update.

### Ty2la vaccine {#CD001261-sec3-0006}

Ty21a is a live oral vaccine derived from an attenuated strain of *S.* Typhi, approved for use in children aged six years or older. It is available as an enteric‐coated capsule and is given in three doses (four doses in North America) every other day. The liquid formulation, which was approved in children over two years old, is not currently available ([@CD001261-bbs2-0121]). It elicits protection that starts 10 to 14 days after the third dose. Travellers should be revaccinated every three to five years with continued or repeat exposure and those living in disease endemic areas every three years. A theoretical question associated with the Ty21a vaccine is whether it reverts to virulence; however, none of the multiple large field trials conducted have documented such hypothetical effects, which are considered exceptionally unlikely given the degree of attenuation ([@CD001261-bbs2-0119]).

### M01ZH09 vaccine {#CD001261-sec3-0007}

A human challenge trial has assessed a new live attenuated oral typhoid vaccine, M01ZH09 ([@CD001261-bbs2-0039]). M01ZH09 is constructed from a parent Ty2 strain. Following vaccination with M01ZH09 or placebo in a double‐blind randomized trial, participants were artificially infected with *S.* Typhi. A single dose was not found to be effective in preventing infection (RR 1.81, 95% CI 0.66 to 5). However, as this was a human challenge, its clinical effects remain unknown.

### Vi polysaccharide vaccine {#CD001261-sec3-0008}

Vi polysaccharide is based on a purified capsular polysaccharide of *S.* Typhi Vi antigen ([@CD001261-bbs2-0093]). Given in a single parenteral dose, protection begins seven days after injection, with maximum protection achieved at 28 days, when the highest antibody concentration is attained ([@CD001261-bbs2-0095]). This vaccine is approved for people aged two years and older. It is not immunogenic in younger children, Revaccination every three years is recommended.

### Typhoid conjugate vaccines {#CD001261-sec3-0009}

Typhoid conjugate vaccines (TCV) are injectable subunit vaccines where Vi capsular polysaccharide antigen is linked to a protein carrier ([@CD001261-bbs2-0093]).

**Vi‐rEPA**, a modified Vi vaccine conjugated to a nontoxic recombinant *Pseudomonas aeruginosa* exotoxin A (rEPA), is given as two parenteral doses. Although theoretically immunogenic from six months old, it has only been used in children over two years ([@CD001261-bbs2-0016]). This vaccine has not been commercialized.

**Vi‐TT**, a new conjugated Vi‐polysaccharide linked to tetanus toxoid carrier protein, has been licensed in India in two preparations: **Peda Typh** (two doses, children six months and above; [@CD001261-bbs2-0017]) and **Typbar‐TCV** (one dose, children six months and above; [@CD001261-bbs2-0050]; [@CD001261-bbs2-0061]). WHO has approved Typbar‐TCV for infants and children over six months of age in endemic areas ([@CD001261-bbs2-0120]).

Why it is important to do this review {#CD001261-sec2-0003}
-------------------------------------

This update of the 2014 Cochrane Review, [@CD001261-bbs2-0123], provides an updated assessment of the efficacy and safety of vaccines to prevent typhoid fever by incorporating data from new trials and vaccines and incorporating cluster‐randomized controlled trials in the meta‐analyses.

Objectives {#CD001261-sec1-0003}
==========

To assess the effects of vaccines for preventing typhoid fever.

Methods {#CD001261-sec1-0004}
=======

Criteria for considering studies for this review {#CD001261-sec2-0004}
------------------------------------------------

### Types of studies {#CD001261-sec3-0010}

Randomized and quasi‐randomized controlled trials.

### Types of participants {#CD001261-sec3-0011}

Adults and children.

### Types of interventions {#CD001261-sec3-0012}

#### Intervention {#CD001261-sec4-0001}

Vaccines against *S.* Typhi include the following.

Live oral vaccine Ty2la or genetic modifications of this strain.Vi polysaccharide vaccine.Conjugate vaccines.

#### Control {#CD001261-sec4-0002}

No vaccine, placebo or typhoid‐inactive agents (vaccine for a different disease)Other typhoid vaccines

For the secondary outcome of adverse events, we included only placebo‐controlled trials.

#### Excluded interventions {#CD001261-sec4-0003}

We excluded studies focusing on the following types of interventions.

Trials that evaluated killed whole‐cell vaccines, because these vaccines are no longer in use.Trials that reported only on immunogenicity.Trials that assessed only adverse events but not clinical efficacy of vaccines that have not yet been evaluated for clinical efficacy.Human challenge studies where participants were artificially infected with*S.* Typhi at a certain time point following vaccination, since the bacterial inoculum in challenge trials is constant and the timing of infection relative to vaccination is highly controlled compared to the real life situation. We therefore believe these trials to be less relevant for clinicians and policy‐making.

### Types of outcome measures {#CD001261-sec3-0013}

#### Primary outcomes {#CD001261-sec4-0004}

##### Typhoid fever {#CD001261-sec5-0001}

Typhoid fever defined by isolation of *S.* Typhi from blood cultures.

#### Secondary outcomes {#CD001261-sec4-0005}

##### Adverse events {#CD001261-sec5-0002}

Serious adverse events, defined as leading to death, requiring inpatient hospitalization or prolonged existing hospitalization, life threatening, or resulting in persistent or significant disability or incapacity.Other adverse events, including fever, erythema at injection site, vomiting, and diarrhoea.

When the occurrence of adverse events was reported after each of several doses, we extracted the occurrence following each dose separately. When reports provided estimates of the incidence of adverse events for different time points after vaccination, we presented the data corresponding to 24 hours after vaccination.

Search methods for identification of studies {#CD001261-sec2-0005}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Databases {#CD001261-sec3-0014}

We searched the following databases using the search terms and strategy described in [Appendix 1](#CD001261-sec2-0015){ref-type="app"}: Cochrane Infectious Diseases Group Specialized Register (searched 14 February 2018); Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2018, Issue 2 of 12); MEDLINE (1966 to 14 February 2018); Embase (1974 to 14 February 2018); and LILACS (1982 to 14 February 2018). We also searched the *meta*Register of Controlled Trials (*m*RCT) using 'typhoid\' and 'vaccine\' as search terms (searched 14 February 2018). We searched the Internet for new drug application (NDA) documents of the US Food and Drug Administration, which may include unpublished studies (last accessed 14 February 2018).

### Conference proceedings {#CD001261-sec3-0015}

We searched the following conference proceedings for relevant abstracts: International Conference on Typhoid and other Invasive Salmonelloses (2013 to 2017); Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ASM Microbe; 1995 to 2017); European Congress of Clinical Microbiology and Infectious Diseases (ECCMID; 2001 to 2017); and the Annual Meeting of the Infectious Diseases Society of America (IDSA; 2001 to 2017).

### Reference lists {#CD001261-sec3-0016}

We examined the reference lists of the included trials.

Data collection and analysis {#CD001261-sec2-0006}
----------------------------

### Selection of studies {#CD001261-sec3-0017}

Two review authors independently inspected titles and abstracts identified by the literature search to identify potentially relevant publications, retrieving the full text of any record that at least one review author judged as potentially relevant. We applied the inclusion criteria for the final decision regarding eligibility. We also ascertained that trials were independent, that is, we looked for multiple publications of the same trial and made sure that we included each trial only once. If a single included reference included more than one trial, we labelled the trials separately using a letter (for example, [@CD001261-bbs2-0022] and [@CD001261-bbs2-0023]). We resolved disagreements by discussion and consensus, documenting reasons for excluding studies from the review. We attempted to contact trial authors for clarification if it was unclear whether a potentially relevant trial was eligible for the review.

### Data extraction and management {#CD001261-sec3-0018}

Two review authors independently extracted data into a standard form; a third review author extracted the data in cases of disagreement. One review author entered data into RevMan 5 ([@CD001261-bbs2-0110]).

### Assessment of risk of bias in included studies {#CD001261-sec3-0019}

Two review authors independently assessed the risk of bias in included trials; in cases of disagreement, we consulted a third review author. We took an individual component approach to quality assessment by using five variables: generation of allocation sequence; allocation concealment; blinding of participants and investigators; inclusion of all randomly assigned participants in the analysis; and reporting of all stated outcomes. We categorized generation of the allocation sequence and allocation concealment as adequate, unclear, or inadequate by using the approach described in [@CD001261-bbs2-0099]. We recorded whether trials used single, double or no blinding, and whether they reported results for all randomized participants.

### Measures of treatment effect {#CD001261-sec3-0020}

We recorded the number of participants experiencing the event and the number analysed in each treatment group. We aimed to extract data according to an intention‐to‐treat analysis and reported any discrepancies in the number randomly assigned and the numbers analysed in each treatment group. We calculated risk ratios with 95% CIs, and in cluster‐RCTs that reported cluster adjusted effect estimates, we extracted the reported effects as risk ratios or hazard ratios.

### Unit of analysis issues {#CD001261-sec3-0021}

For trials randomly assigning clusters, we extracted cluster‐adjusted effect estimates when available. We also recorded the number of clusters in the trial, the average size of clusters, the unit of randomization (for example, household or institution) and the statistical methods used to analyse the trial results. For cluster‐RCTs reporting individual patient results without adjustment for clustering, we calculated an intracluster correlation coefficient (ICC) using trial data from [@CD001261-bbs2-0021] (that allowed calculation of unadjusted risk ratios from crude number of individuals and reported cluster‐adjusted hazard ratios) as 0.0015. We calculated the design effect of cluster‐RCTs that did not adjust for clustering taking into account average cluster size. We used this design effect to calculate the effective number of events per control and intervention and the effective number of participants per control and intervention to be used in the meta‐analysis. We present cluster‐unadjusted results in a separate table but do not use them in the meta‐analysis.

If a single included trial compared several vaccine arms with a control arm, we labelled the arms separately using a Roman numeral (for example, [@CD001261-bbs2-0002] and [@CD001261-bbs2-0003]). To avoid including data for controls more than once in the same comparison, we divided the placebo group into equal parts while assuming equal incidence in these groups.

### Dealing with missing data {#CD001261-sec3-0022}

When necessary, we contacted the trial authors for clarification or additional details regarding trial methodology or results. In cluster‐RCTs, we asked authors for distribution of outcomes in the different clusters.

### Assessment of heterogeneity {#CD001261-sec3-0023}

We assessed heterogeneity by inspecting the forest plots to detect overlapping CIs and the I^2^ statistic used to denote levels of heterogeneity as defined in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD001261-bbs2-0097]).

0% to 40% heterogeneity: might not be important.30% to 60%: may represent moderate heterogeneity.50% to 90%: may represent substantial heterogeneity.75% to 100%: considerable heterogeneity.

### Assessment of reporting biases {#CD001261-sec3-0024}

We planned to inspect funnel plots to assess small study effects and explore the possibility of reporting bias. However, all analyses included too few trials to analyse the funnel plot.

### Data synthesis {#CD001261-sec3-0025}

We conducted separate meta‐analyses for each vaccine type. We combined dichotomous data from trials that randomly assigned individuals or corrected numbers from cluster‐RCTs that did not adjust by using risk ratios (RRs) with 95% CIs. In analyses including cluster‐RCTs that reported adjusted risk ratios, we pooled risk ratios from all the trials using inverse variance meta‐analysis. We interpreted the results as efficacy, defined as 1 − RR and expressed as a percentage. We analysed efficacy per year and cumulative efficacy, as they provide different information. Analyses per year show whether the effect of the vaccine decreases over time, and cumulative efficacy demonstrates efficacy overall, for a given period up to three years and longer if available, regardless of whether changes over time occurred within this period. We rounded to the nearest year when trials included follow‐up for only part of a year. The random‐effects model was used throughout the review. We calculated number needed to treat for an additional beneficial outcome (NNTB) (1/reduction in risk of typhoid fever attributable to vaccination) for each type of vaccine based on the cumulative 2.5 to 3‐year point estimate and the incidence of typhoid fever in control groups of trials assessing the given vaccination.

### Subgroup analysis and investigation of heterogeneity {#CD001261-sec3-0026}

We had planned to explore the following potential sources of heterogeneity in subgroup analyses: number of doses; length of follow‐up; type of oral formulation in the Ty21a vaccine (capsules and type of capsule, liquid formulation) and age. However, data were sparse, so we present only the subgroup by type of oral formulation in the meta‐analyses.

### Sensitivity analysis {#CD001261-sec3-0027}

We conducted sensitivity analyses by limiting the meta‐analysis to trials at low of risk of bias due to randomization methods for the primary outcome and assessing whether vaccine efficacy changed. We considered that blinding would not affect bias for our primary outcome of typhoid fever cases, as this measure is objective ([@CD001261-bbs2-0112]).

#### 'Summary of findings\' table {#CD001261-sec4-0006}

We assessed the certainty of the evidence across each outcome measure using the GRADE approach. The certainty rating across studies has one of four levels: high, moderate, low or very low. GRADE initially classifies randomized trials as high certainty, downgrading may be warranted after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias ([@CD001261-bbs2-0096]). The 'Summary of findings\' tables present the main results of the review and the certainty assessments.

Results {#CD001261-sec1-0005}
=======

Description of studies {#CD001261-sec2-0007}
----------------------

### Results of the search {#CD001261-sec3-0028}

We present the search results in a PRISMA study flow diagram in [Figure 1](#CD001261-fig-0001){ref-type="fig"}. In the previous version of this review, [@CD001261-bbs2-0123], we included 32 publications of 19 trials (the previous version misreported this number, but we have corrected it in the update). We excluded one study that was in the previous review, [@CD001261-bbs2-0073], due to the refining of the inclusion criteria for adverse events trials. We updated the literature search to 14 February 2018 and identified 50 new unique records. We assessed 13 full‐text articles for eligibility after abstract screening. One new trial met the inclusion criteria ([@CD001261-bbs2-0017]), while three trials were ongoing (see the [Characteristics of ongoing studies](#CD001261-sec2-0021){ref-type="sec"} section).Figure 1Study flow diagram.

### Included studies {#CD001261-sec3-0029}

In total, 32 records reporting on 19 trials (12 RCTs randomizing individuals and 7 cluster‐RCTs) met the inclusion criteria: see details in [Characteristics of included studies](#CD001261-sec2-0019){ref-type="sec"} table. The 2018 review update includes one new trial evaluating the efficacy of Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi‐TT), PedaTyph ([@CD001261-bbs2-0017]).

All of the trials except [@CD001261-bbs2-0005] took place in countries where typhoid fever is endemic: Chile (four trials), China (three trials), Vietnam (one trial), Thailand (two trials), Pakistan (one trial), Egypt (one trial), India (two trials), Indonesia (one trial), Nepal (one trial), and South Africa (one trial). None of the trials evaluated vaccine efficacy in travellers from developed countries or compared the efficacy of different types of typhoid vaccines.

Participants ranged in age across the trials. Three trials included children aged under 12 years only ([@CD001261-bbs2-0016]; [@CD001261-bbs2-0017]; [@CD001261-bbs2-0022]), and one trial reported on adults only ([@CD001261-bbs2-0008]). Only three efficacy trials included data on adults over 25 years of age ([@CD001261-bbs2-0001]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0024]). None of the trials reported on use of typhoid vaccination in adults aged over 55 years. Only one trial included children under two years of age ([@CD001261-bbs2-0017]). All trials either excluded pregnant participants or included no details on their inclusion.

#### Outcomes {#CD001261-sec4-0007}

Data on the primary outcome, cases of typhoid fever, were derived from 13 trials.

Five trials of Ty21a ([@CD001261-bbs2-0002]; [@CD001261-bbs2-0003]; [@CD001261-bbs2-0010]; [@CD001261-bbs2-0011]; [@CD001261-bbs2-0012]; [@CD001261-bbs2-0013]; [@CD001261-bbs2-0014]; [@CD001261-bbs2-0015]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0020]; [@CD001261-bbs2-0022]).Six trials of Vi polysaccharide ([@CD001261-bbs2-0001]; [@CD001261-bbs2-0006]; [@CD001261-bbs2-0007]; [@CD001261-bbs2-0021]; [@CD001261-bbs2-0024]; [@CD001261-bbs2-0025]).One Vi‐rEPA trial ([@CD001261-bbs2-0016]).One Vi‐TT (PedaTyph) trial ([@CD001261-bbs2-0017]).

Data on the secondary outcome, adverse events, came from nine trials.

Five trials of Ty21a ([@CD001261-bbs2-0008]; [@CD001261-bbs2-0009]; [@CD001261-bbs2-0018]; [@CD001261-bbs2-0022]; [@CD001261-bbs2-0023]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0020]).Three trials of Vi polysaccharide ([@CD001261-bbs2-0005]; [@CD001261-bbs2-0025]; [@CD001261-bbs2-0026]).One trial of Vi‐rEPA ([@CD001261-bbs2-0016]).

One additional individual RCT assessed the Ty21a vaccine and reported on adverse events but did not provide the number of participants per study arm ([@CD001261-bbs2-0004]); therefore we do not include results of this trial in the meta‐analysis.

### Excluded studies {#CD001261-sec3-0030}

In this 2018 update we excluded nine trials. Across all versions of this review, we excluded 60 publications (53 trials). For details of excluded trials and reasons for their exclusion, see the [Characteristics of excluded studies](#CD001261-sec2-0020){ref-type="sec"} table.

Risk of bias in included studies {#CD001261-sec2-0008}
--------------------------------

See [Figure 2](#CD001261-fig-0002){ref-type="fig"} for a summary of the 'Risk of bias\' assessment and the [Characteristics of included studies](#CD001261-sec2-0019){ref-type="sec"} for further details on the reasons for review authors\' judgements.Figure 2Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD001261-sec3-0031}

Six of the 13 trials reporting on efficacy reported low‐risk randomization procedures ([@CD001261-bbs2-0006]; [@CD001261-bbs2-0017]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0020]; [@CD001261-bbs2-0021]; [@CD001261-bbs2-0024]; [@CD001261-bbs2-0025]). The other seven trials did not provide enough information to permit judgement. All but one trial, [@CD001261-bbs2-0007], used low‐risk methods to conceal allocation.

Three of the 10 trials reporting adverse events described low‐risk randomization procedures ([@CD001261-bbs2-0019]; [@CD001261-bbs2-0020]; [@CD001261-bbs2-0025]; [@CD001261-bbs2-0026]). Likewise, three used low‐risk methods to conceal allocation ([@CD001261-bbs2-0016]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0020]; [@CD001261-bbs2-0025]). The other trials did not report enough information to permit judgement.

### Blinding {#CD001261-sec3-0032}

All but 3 of the 13 trials on clinical efficacy used double‐blinding. Two cluster‐randomized trials could not guarantee blinding of researchers or participants, as they used vaccines that were packaged differently and therefore did not look identical ([@CD001261-bbs2-0006]; [@CD001261-bbs2-0021]). However, both trials tried to minimize this effect by assigning each vaccination team to only one vaccine, identifying the vaccines only by code, and not informing local research staff members or participants of the assignment of the code or the vaccine. One cluster‐randomized trial, [@CD001261-bbs2-0017], was open label with no placebo arm, with the control group having vaccinations as per the normal schedule. There is no information as to whether researchers were blinded.

All of the trials that included adverse effects used double‐blinding.

### Incomplete outcome data {#CD001261-sec3-0033}

Ten of 13 trials that investigated vaccine efficacy included all randomly assigned participants in the analysis, so we classified them at low risk of attrition bias. Three trials provided no reasons for missing data ([@CD001261-bbs2-0002]; [@CD001261-bbs2-0003]; [@CD001261-bbs2-0010]; [@CD001261-bbs2-0011]; [@CD001261-bbs2-0012]; [@CD001261-bbs2-0013]; [@CD001261-bbs2-0014]; [@CD001261-bbs2-0015]).

We assessed 5 of 10 trials that included adverse events as being at low risk in terms of including all randomly assigned participants in the analysis or providing reasons for missing outcome data. Two trials were unclear on this issue ([@CD001261-bbs2-0004]; [@CD001261-bbs2-0008]; [@CD001261-bbs2-0009]). We judged the trial that did not provide the number of participants per study arm as being at high risk of attrition bias ([@CD001261-bbs2-0004]).

### Selective reporting {#CD001261-sec3-0034}

All but one of the 13 trials on vaccine efficacy reported on pre‐planned outcomes, meriting a classification of low risk of bias. [@CD001261-bbs2-0017] did not report on paratyphoid outcomes as the prospectively registered protocol had described, so we classified it as being at high risk of bias. The vaccine assessed would not have affected the incidence of *S.* Paratyphi infections but would have aided us to judge whether the decreased number of infections was due to the effect of the vaccine or consequences of better socioeconomic status of the immunized group (see other sources of bias described below).

All 10 trials included in the adverse events analysis reported on plausible outcomes, so we classified them as being at low risk of bias, even though protocols were not available.

### Other potential sources of bias {#CD001261-sec3-0035}

Four of the seven cluster‐RCTs on vaccine efficacy provided data on the efficacy of the Ty21a vaccine ([@CD001261-bbs2-0002]; [@CD001261-bbs2-0010]; [@CD001261-bbs2-0014]; [@CD001261-bbs2-0022]). These four cluster‐RCTs, all of which randomly assigned by classroom, did not adjust for clustering in their results.

Two of the vaccine efficacy cluster‐RCTs provided data on the efficacy of the Vi polysaccharide vaccine ([@CD001261-bbs2-0006]; [@CD001261-bbs2-0021]). Both of these trials randomly assigned geographic clusters. Study authors provided unpublished cluster‐adjusted data for the meta‐analysis.

The remaining vaccine efficacy cluster‐RCT provided data on the efficacy of the Vi‐TT conjugate vaccine PedaTyph ([@CD001261-bbs2-0017]). The trial cluster‐randomized children by school and did not adjust for clustering in the sample size calculations or in results. The intervention and control groups were different in terms of socioeconomic data, despite randomization, with lower status in the control group. As typhoid fever is associated with poor sanitation and hygiene, it is plausible that the vaccine would prevent more cases in lower socioeconomic groups. Although the authors did not mention it in the published paper, according to the prospectively registered protocol the company who manufactures Peda Typh funded the study. We classified this trial as being at high risk of other sources of bias.

Effects of interventions {#CD001261-sec2-0009}
------------------------

See: [Table 1](#CD001261-tbl-0001){ref-type="table"}; [Table 2](#CD001261-tbl-0002){ref-type="table"}; [Table 3](#CD001261-tbl-0003){ref-type="table"}; [Table 4](#CD001261-tbl-0004){ref-type="table"}

### TY21a vaccine {#CD001261-sec3-0036}

#### Efficacy {#CD001261-sec4-0008}

Investigators assessed the TY21a vaccine in one four‐arm individual RCT, [@CD001261-bbs2-0019], and four cluster‐RCTs, reported in [@CD001261-bbs2-0003][@CD001261-bbs2-0010][@CD001261-bbs2-0011][@CD001261-bbs2-0012][@CD001261-bbs2-0013][@CD001261-bbs2-0014][@CD001261-bbs2-0015] and [@CD001261-bbs2-0022]. The cluster‐RCTs did not adjust analyses for the effect of clustering, so they may have overestimated any protective effect. We adjusted results from these trials using an estimated ICC of 0.0015 and average cluster size to calculate the design effect so we could include them in the meta‐analysis. [Table 14](#CD001261-tbl-0014){ref-type="table"} displays adjusted results, and we refer to these findings unless otherwise specified. [Table 15](#CD001261-tbl-0015){ref-type="table"} shows unadjusted results.Table 1Cluster‐randomized trials: efficacy of oral Ty21a (3 doses) versus control; adjusted results**TrialYearPreparation (N doses)ICC^a^Average cluster sizeDesign effectTyphoid episodes/ participants in intervention groupTyphoid episodes/ participants in in control groupRisk ratio (95% CI)**[@CD001261-bbs2-0010]1Enteric capsules (3)0.0015251.0367/21,4006/52860.29 (0.10 to 0.86)21.0368/21,4005/52860.40 (0.13 to 1.21)31.0368/21,4006/52860.33 (0.11 to 0.95)[@CD001261-bbs2-0022]1Liquid formulation (3)0.0015371.0540/13,9807/15,0870.07 (0.00 to 1.26)21.0540/13,9808/15,0870.06 (0.00 to 1.10)31.0540/13,9807/15,0870.07 (0.00 to 1.26)[@CD001261-bbs2-0010]Cumulative incidence\
2.5 to 3 yearsEnteric capsules (3)0.0015251.03633/20,84716/52860.52 (0.29 to 0.95)[@CD001261-bbs2-0011]Cumulative incidence\
2.5 to 3 yearsEnteric capsules (3)0.0015251.03622/21,40016/52860.34 (0.18 to 0.65)[@CD001261-bbs2-0015]Cumulative incidence\
2.5 to 3 yearsEnteric capsules (3)0.0015151.02162/33,98214/47520.62 (0.35 to 1.11)[@CD001261-bbs2-0022]Cumulative incidence\
2.5 to 3 yearsLiquid formulation (3)0.001537^b^1.0540/13,98021/15,0870.03 (0.00 to 0.41)[@CD001261-bbs2-0014]Cumulative incidence\
2.5 to 3 yearsLiquid formulation (3)0.0015151.02123/35,87014/53380.24 (0.13 to 0.47)[@CD001261-bbs2-0012]Cumulative incidence\
2.5 to 3 yearsGelatin capsules (3)0.0015251.03644/20,79216/52860.70 (0.39 to 1.24)[@CD001261-bbs2-0013]Cumulative incidence\
2.5 to 3 yearsGelatin capsules (3)0.0015261.037554/21,57016/52790.83 (0.47 to 1.44)[@CD001261-bbs2-0014]Cumulative incidence\
5 yearsLiquid formulation (3)0.015151.02133/35,87021/53380.23 (0.14 to 0.40)[@CD001261-bbs2-0011]Cumulative incidence\
7 yearsEnteric capsules (3)0.015251.03648/21,40032/52860.37 (0.24 to 0.58)[^6]Table 2Cluster‐randomized trials: efficacy of oral Ty21a vaccine: unadjusted results^a^**TrialYearPreparation (N doses)RR (95% CI)^b^Efficacy^c^**[@CD001261-bbs2-0003]1Enteric capsules (1)0.75 (0.48 to 1.18)25% (−18% to 52%)20.65 (0.36 to 1.18)35% (−18% to 64%)31.04 (0.47 to 2.31)−4% (−131% to 53%)41.06 (0.56 to 2.00)−6% (−100% to 44%)51.17 (0.51 to 2.68)−17% (−168% to 49%)Cumulative 3 years0.76 (0.55 to 1.06)24% (−6% to 45%)Cumulative 5 years0.85 (0.65 to 1.12)15% (−12% to 35%)[@CD001261-bbs2-0002]1Enteric capsules (2)0.48 (0.29 to 0.79)52% (21% to 71%)20.29 (0.14 to 0.60)71% (40% to 86%)30.74 (0.33 to 1.65)26% (−65% to 67%)40.81 (0.42 to 1.58)19% (−58% to 58%)50.88 (0.39 to 1.99)12% (‐99% to 61%)Cumulative 3 years0.46 (0.32 to 0.66)54% (34% to 68%)Cumulative 5 years0.57 (0.42 to 0.76)43% (24% to 58%)[@CD001261-bbs2-0011]1Enteric capsules (3)0.29 (0.10 to 0.86)71% (14% to 90%)20.40 (0.13 to 1.21)60% (−21% to 87%)30.33 (0.11 to 0.95)67% (5% to 89%)[@CD001261-bbs2-0022]1Liquid formulation (3)0.07 (0.00 to 1.26)93% (−26% to 100%)20.06 (0.00 to 1.10)94% (−10% to 100%)30.07 (0.00 to 1.26)93% (−26% to 100%)[@CD001261-bbs2-0010]Cumulative incidence 2.5 to 3 yearsEnteric capsules (3)0.51 (0.28 to 0.91)49% (9% to 72%)[@CD001261-bbs2-0011]Cumulative incidence 2.5 to 3 yearsEnteric capsules (3)0.33 (0.18 to 0.63)67% (82% to 37%)[@CD001261-bbs2-0015]Cumulative incidence 2.5 to 3 yearsEnteric capsules (3)0.63 (0.35 to 1.12)37% (−12% to 65%)[@CD001261-bbs2-0022]Cumulative incidence 2.5 to 3 yearsLiquid formulation (3)0.02 (0.00 to 0.40)98% (60% to 100%)[@CD001261-bbs2-0014]Cumulative incidence 2.5 to 3 yearsLiquid formulation (3)0.24 (0.13 to 0.47)76% (53% to 87%)[@CD001261-bbs2-0012]Cumulative incidence 2.5 to 3 yearsGelatin capsules (3)0.69 (0.39 to 1.20)31% (−20% to 61%)[@CD001261-bbs2-0013]Cumulative incidence 2.5 to 3 yearsGelatin capsules (3)0.81 (0.47 to 1.39)19% (−39% to 53%)[@CD001261-bbs2-0014]Cumulative incidence 5 yearsLiquid preparation (3)0.23 (0.13 to 0.39)77% (61% to 87%)[@CD001261-bbs2-0011]Cumulative incidence 7 yearsEnteric capsules (3)0.37 (0.24 to 0.58)63% (42% to 76%)[^7]

A three‐dose schedule of Ty21a vaccine provided vaccine efficacy of 45% at year 1 (95% CI 14% to 65%; 76,296 participants; [Analysis 1.1](#CD001261-fig-00101){ref-type="fig"}), 59% at year 2 (95% CI 43% to 71%; 76,296 participants; [Analysis 1.2](#CD001261-fig-00102){ref-type="fig"}) and 56% at year 3 (95% CI 24% to 75%; 76,296 participants; [Analysis 1.3](#CD001261-fig-00103){ref-type="fig"}). The cumulative efficacy of the Ty21a vaccine over 2.5 to 3 years was 50% (95% CI 35% to 61%; 235,239 participants; [Analysis 1.4](#CD001261-fig-00104){ref-type="fig"}).

Cumulative efficacy of the three‐dose schedule of Ty21a vaccine for over three years is available from two of the adjusted cluster‐RCTs ([@CD001261-bbs2-0011]; [@CD001261-bbs2-0014]). Cumulative efficacy was 77% at five years (95% CI 60% to 86%; [Table 14](#CD001261-tbl-0014){ref-type="table"}) and 63% at seven years (95% CI 42% to 76%; [Table 14](#CD001261-tbl-0014){ref-type="table"}).

We were unable to conduct subgroup analysis by age, as trials evaluating the efficacy of the Ty21a vaccine did not stratify results according to this variable.

In the cumulative analysis there is moderate heterogeneity that is not explained by stratifying results by type of preparation. In direct randomized comparisons between liquid and enteric capsules ([Analysis 2.1](#CD001261-fig-00201){ref-type="fig"}) and between enteric and gelatin capsules ([Analysis 3.1](#CD001261-fig-00301){ref-type="fig"}), the heterogeneity was too high to pool the results, so we were unable to conduct a meta‐analysis.

#### Adverse events {#CD001261-sec4-0009}

None of the individual‐ or cluster‐randomized trials reported any serious adverse events (5 trials, 235,239 participants: [@CD001261-bbs2-0008]; [@CD001261-bbs2-0009]; [@CD001261-bbs2-0018]; [@CD001261-bbs2-0022]; [@CD001261-bbs2-0023]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0020]; [Appendix 2](#CD001261-sec2-0016){ref-type="app"}).

Compared with placebo, the Ty21a vaccine (both preparations) did not increase the incidence of vomiting (2 trials, 2066 participants; [Analysis 4.2](#CD001261-fig-00402){ref-type="fig"}), diarrhoea (2 trials, 2066 participants; [Analysis 4.3](#CD001261-fig-00403){ref-type="fig"}), nausea or abdominal pain (2 trials, 2066 participants; [Analysis 4.4](#CD001261-fig-00404){ref-type="fig"}), headache (1 trial, 1190 participants; [Analysis 4.5](#CD001261-fig-00405){ref-type="fig"}), or rash (1 trial, 1190 participants; [Analysis 4.6](#CD001261-fig-00406){ref-type="fig"}) compared with control. However, fever was more common after vaccine delivery (RR 1.84, 95% CI 1.02 to 3.05; 2 trials, 2066 participants). A pooled analysis of two individual‐RCTs showed a marginal increase in risk of any mild adverse events (RR 1.67, 95% CI 1.03 to 2.72; 2 trials, 1360 participants; [Analysis 4.7](#CD001261-fig-00407){ref-type="fig"}).

The cluster‐randomized studies [@CD001261-bbs2-0022] and [@CD001261-bbs2-0023] reported adverse events per dose of vaccine rather than per patient, so we could use these data in the meta‐analysis. There appeared to be more episodes of vomiting and nausea/abdominal pain per dose with the vaccine, but the overall incidence was low (0.1% vomiting with Ty21a versus 0.05% with placebo; 0.03% nausea/abdominal pain with Ty21a versus 0.004% with placebo, [Appendix 2](#CD001261-sec2-0016){ref-type="app"}).

[@CD001261-bbs2-0004] did not supply the number of participants in the vaccine and placebo groups, so results could not be analysed. Authors noted that all reactions were mild.

See [Table 1](#CD001261-tbl-0001){ref-type="table"}.

### Vi polysaccharide vaccine {#CD001261-sec3-0037}

#### Efficacy {#CD001261-sec4-0010}

Four individually randomized RCTs assessed the efficacy of this vaccine ([@CD001261-bbs2-0001]; [@CD001261-bbs2-0007]; [@CD001261-bbs2-0024]; [@CD001261-bbs2-0025]), as did two cluster‐RCTs ([@CD001261-bbs2-0006]; [@CD001261-bbs2-0021]). We obtained cluster‐adjusted results for efficacy at year 2 following vaccination from the study authors, so we were able to pool the results from the individually randomized RCTs and the cluster‐adjusted RCTs using the generic inverse variance method.

The efficacy of the Vi polysaccharide vaccine was 69% at year 1 (95% CI 63% to 74%; 3 trials, 99,797 participants; [Analysis 5.1](#CD001261-fig-00501){ref-type="fig"}) and 59% at year 2 (95% CI 45% to 69%; 4 trials, 194,969 participants; [Analysis 5.1](#CD001261-fig-00501){ref-type="fig"}) There was high heterogeneity in year 2 (I^2^ = 72%), which we were unable to explain with subgroup analysis. Ty21a efficacy was 50% at year 3 based on a single trial (95% CI 22% to 68%; 11,384 participants; [Analysis 5.1](#CD001261-fig-00501){ref-type="fig"}). Cumulative efficacy at 2.5 to 3 years, based on the same single trial ([@CD001261-bbs2-0007]), was 55% (95% CI 30% to 70%; 11,384 participants; [Analysis 5.2](#CD001261-fig-00502){ref-type="fig"}).

Two of the trials used the Widal test (as well as a positive culture) to detect cases of typhoid fever ([@CD001261-bbs2-0024]; [@CD001261-bbs2-0025]). Results of the Widal test were not included in the meta‐analysis. Both trials followed participants for six years, and their combined culture‐based results demonstrated that protection was significant in each of the first two years but not in years 3 or 6. Three‐year cumulative efficacy was 69% (95% CI 50% to 81%), and combined efficacy for years 4 through 6 was 11% (95% CI −76% to 55%) (analyses not shown).

Three of the RCTs conducted subgroup analysis by age: [@CD001261-bbs2-0025] used individual randomization, while [@CD001261-bbs2-0006] and [@CD001261-bbs2-0021] were cluster trials. However, the individually based RCT included very small numbers in each age group ([@CD001261-bbs2-0025]); the two cluster‐RCTs did not adjust for clustering and presented their results in the form of hazard ratios rather than risk ratios (with effectiveness of vaccination estimated as: (1 − hazard ratio) × 100% ([@CD001261-bbs2-0006]; [@CD001261-bbs2-0021]). We were therefore unable to conduct subgroup analysis by age. [Table 16](#CD001261-tbl-0016){ref-type="table"} presents unadjusted results by age from the two cluster‐RCTs. The cluster‐randomized trial conducted in India, [@CD001261-bbs2-0021], found that two years after vaccination, the Vi polysaccharide vaccine provided significantly more protection than the control condition for children two to five years of age (efficacy 82%, 95% CI 58% to 92%). However, contrary to these results, the cluster‐randomized trial conducted in Pakistan, [@CD001261-bbs2-0006] showed no protection among children between two and five years of age compared with placebo at two years after vaccination (efficacy −30%, 95% CI −183% to 40%).Table 3Efficacy of Vi polysaccharide vaccine: unadjusted cluster‐trial results by age^a^**TrialYearAge at baselineTyphoid episodes:Vi vaccineTyphoid episodes:controlEfficacy (95% CI):not adjusted**[@CD001261-bbs2-0006]Cumulative incidence at 2 years2 to \< 5 years16/315413/3324−30% (−183% to 40%)5 to 16 years14/10,08436/10,66959% (9% to 81%)[@CD001261-bbs2-0021]Cumulative incidence at 2 years2 to \< 5 years5/109727/109582% (58% to 92%)5 to \< 15 years21/428254/458459% (18% to 79%≥ 15 years8/13,49015/13,12548% (−44% to 81%)[^8]

#### Adverse events {#CD001261-sec4-0011}

No trials reported on serious adverse events.

Overall, we did not find a significant difference between vaccine and placebo in the incidence of fever (3 trials, 132,261 participants; [Analysis 6.1](#CD001261-fig-00601){ref-type="fig"}) or erythema (3 trials, 132,261 participants; [Analysis 6.2](#CD001261-fig-00602){ref-type="fig"}). However, swelling (RR 6.06, 95% CI 1.07 to 34.22; 3 trials, 1767 participants; [Analysis 6.3](#CD001261-fig-00603){ref-type="fig"}) and pain at the injection site (RR 7.98, 95% CI 3.69 to 17.24; 1 trial, 667 participants; [Analysis 6.4](#CD001261-fig-00604){ref-type="fig"}) were more common after delivery of the Vi polysaccharide vaccine.

See [Table 2](#CD001261-tbl-0002){ref-type="table"}.

### Vi‐rEPA vaccine {#CD001261-sec3-0038}

#### Efficacy {#CD001261-sec4-0012}

One trial in children aged two to five years, conducted in Vietnam, evaluated the efficacy of this vaccine ([@CD001261-bbs2-0016]), reporting that it was 94% at year 1 (95% CI 75% to 99%; 12,008 participants; [Analysis 7.1](#CD001261-fig-00701){ref-type="fig"}) and 87% in year 2 (95% CI 56% to 96%; 12,008 participants; [Analysis 7.1](#CD001261-fig-00701){ref-type="fig"}), with a two‐year cumulative efficacy of 91% (95% CI 78% to 96%; 12,008 participants; [Analysis 7.1](#CD001261-fig-00701){ref-type="fig"}). The cumulative efficacy of the Vi‐rEPA vaccine after 3.8 years was 89% (95% CI 77% to 95%; 12,008 participants, [Analysis 7.1](#CD001261-fig-00701){ref-type="fig"}). The planned vaccine schedule was two doses of vaccine approximately six weeks apart. Although 388 children in the vaccine group received only one dose of vaccine instead of two, authors still analysed them along with those who had received two doses. The cumulative two‐year efficacy for two doses of vaccine was the same as for one or two doses of vaccine, so this did not seem to undermine the validity of the results.

No trials assessed the efficacy of this vaccine in children older than five or in adults.

#### Adverse events {#CD001261-sec4-0013}

One trial evaluated adverse events associated with this vaccine, reporting no serious events ([@CD001261-bbs2-0016]). Fever was more common following delivery of both the first and second vaccinations with Vi‐rEPA compared with placebo (dose 1: RR 2.54, 95% CI 1.69 to 3.82, 12,008 participants, 1 trial, [Analysis 8.1](#CD001261-fig-00801){ref-type="fig"}; dose 2: RR 4.39, 95% CI 2.85 to 6.77, 11,091 participants, 1 trial, [Analysis 8.2](#CD001261-fig-00802){ref-type="fig"}). After the first dose of Vi‐rEPA, no participants in either the test or placebo group reported erythema or swelling at the injection site ([Analysis 8.3](#CD001261-fig-00803){ref-type="fig"}; [Analysis 8.5](#CD001261-fig-00805){ref-type="fig"}). After the second dose, there was no significant difference between the vaccine and placebo for erythema ([Analysis 8.4](#CD001261-fig-00804){ref-type="fig"}), but swelling at the injection site was more common in the Vi‐rEPA group (RR 20.15, 95% CI 2.71 to 150.8; 11,091 participants, 1 trial; [Analysis 8.6](#CD001261-fig-00806){ref-type="fig"}).

See [Table 3](#CD001261-tbl-0003){ref-type="table"}.

### Vi‐tetanus toxoid conjugated typhoid vaccine (Pedatyph) {#CD001261-sec3-0039}

#### Efficacy {#CD001261-sec4-0014}

One cluster‐randomized trial in children aged six months to 12 years of age assessed the efficacy of this vaccine in India ([@CD001261-bbs2-0017]). The authors did not adjust for cluster randomization. Using an estimated ICC of 0.0015 (from [@CD001261-bbs2-0021]) and an average cluster size of 135, we calculated the design effect as 1.201 and adjusted results accordingly. [Table 17](#CD001261-tbl-0017){ref-type="table"} shows unadjusted results.Table 4Efficacy of Vi‐TT (PedaTyph); cluster unadjusted results; year 1**TrialNumber of**\
**dosesFollow‐upVi‐TT (PedaTyph)ControlRisk ratio (96% CI)Efficacy (95% CI)EventsTotalEventsTotal**[@CD001261-bbs2-0017]21 year0765118600.05 (0.00 to 0.83%)95% (17% to 100%)[^9]

The adjusted efficacy of Vi‐TT (PedaTyph, 2 doses) at one‐year follow‐up was 94% (95% CI −1% to 100%; 1625 participants; [Analysis 9.1](#CD001261-fig-00901){ref-type="fig"}).

#### Adverse effects {#CD001261-sec4-0015}

The trial did not report any serious adverse effects.

See [Table 4](#CD001261-tbl-0004){ref-type="table"}.

### Heterogeneity {#CD001261-sec3-0040}

Other than where already stated, in most comparisons that included several trials, the degree of heterogeneity was not substantial (that is, I^2^ statistic \< 50% and Chi^2^ test with P value \> 0.10). However, because of the limited number of trials included in each comparison, we were unable to identify the reason for the greater degree of heterogeneity in some comparisons.

### Sensitivity analyses {#CD001261-sec3-0041}

We performed sensitivity analyses for trials with a split control arm in the main analyses and found that the results did not change (analyses not shown). As most comparisons included few trials, we could not perform sensitivity analyses according to risk of bias. We did not notice any difference in adverse event results from trials that did and did not evaluate efficacy, although we did not undertake formal testing.

### Number needed to treat for an additional beneficial outcome (NNTB) to prevent one case of typhoid fever {#CD001261-sec3-0042}

#### Ty21a vaccine {#CD001261-sec4-0016}

The liquid formulation of the Ty21a vaccine had a three‐year cumulative protective efficacy of 71% (95% CI 34% to 88%; [@CD001261-bbs2-0014]; [@CD001261-bbs2-0019]; [@CD001261-bbs2-0022]; [Analysis 1.4](#CD001261-fig-00104){ref-type="fig"}). The incidence rate in the control group was 544/100,000 with a corresponding NNTB of 259 (95% CI 209 to 541). The enteric capsule formulation of the Ty21a vaccine had three‐year cumulative protective efficacy of 46% (95% CI 32% to 58%; [@CD001261-bbs2-0010]; [@CD001261-bbs2-0011]; [@CD001261-bbs2-0015]; [@CD001261-bbs2-0020]; [Analysis 1.4](#CD001261-fig-00104){ref-type="fig"}). The incidence in the control group was 734/100,000, and the corresponding NNTB was 296 (95% CI 235 to 426).

#### Vi polysaccharide vaccine {#CD001261-sec4-0017}

The Vi polysaccharide vaccine has a 2.5‐ to 3‐year cumulative protective efficacy of 55% (95% CI 30% to 70%; [@CD001261-bbs2-0007]; [Analysis 4.2](#CD001261-fig-00402){ref-type="fig"}), with an incidence rate of 1160/100,000. From these data, we estimated the NNTB to be 157 (95% CI 1234 to 287).

Discussion {#CD001261-sec1-0006}
==========

Summary of main results {#CD001261-sec2-0010}
-----------------------

### Ty21a vaccine (three doses) {#CD001261-sec3-0043}

A three‐dose schedule of Ty21a vaccine probably prevents around half of typhoid cases during the first three years after vaccination (moderate‐certainty evidence). These data include patients aged 3 to 44 years.

Compared with placebo, this vaccine probably does not cause more vomiting, diarrhoea, nausea, or abdominal pain, (moderate‐certainty evidence) headache, or rash (moderate‐certainty evidence); however, fever is probably more common following vaccination (moderate‐certainty evidence).

See [Table 1](#CD001261-tbl-0001){ref-type="table"}.

### Vi polysaccharide vaccine (one dose) {#CD001261-sec3-0044}

A single dose of Vi polysaccharide vaccine prevents around two‐thirds of typhoid cases in the first year after vaccination (high‐certainty evidence). In year 2, trial results were more variable, with the vaccine probably preventing between 45% and 69% of typhoid cases (moderate‐certainty evidence). These data included participants aged 2 to 55 years of age. The three‐year cumulative efficacy of the vaccine may be around 55% (low‐certainty evidence). These data were taken from a single trial conducted in South Africa in the 1980s in participants aged 5 to 15 years.

Compared with placebo, this vaccine probably did not increase the incidence of fever (moderate‐certainty evidence) or erythema (low‐certainty evidence); however, swelling (moderate‐certainty evidence) and pain at the injection site (moderate‐certainty evidence) were more common in the vaccine group.

See [Table 2](#CD001261-tbl-0002){ref-type="table"}.

### Vi‐rEPA vaccine (two doses) {#CD001261-sec3-0045}

Administration of two doses of the Vi‐rEPA vaccine probably prevents between 50% and 96% of typhoid cases during the first two years after vaccination (moderate‐certainty evidence). These data were taken from a single trial with children two to five years of age conducted in Vietnam.

Compared with placebo, both the first and the second dose of this vaccine increased the risk of fever (low‐certainty evidence) and the second dose increased the incidence of swelling at the injection site (moderate‐certainty evidence).

See [Table 3](#CD001261-tbl-0003){ref-type="table"}.

### Vi‐TT vaccine (two doses) {#CD001261-sec3-0046}

We are uncertain of the efficacy of administering two doses of Vi‐TT (PedaTyph) in typhoid cases in children during the first year after vaccination (very low‐certainty evidence). These data are taken from a single cluster‐randomized trial in children aged six months to 12 years conducted in India.

See [Table 4](#CD001261-tbl-0004){ref-type="table"}.

WIth all vaccines, there were no reported serious adverse effects in RCTs.

Overall completeness and applicability of evidence {#CD001261-sec2-0011}
--------------------------------------------------

In the absence of trials directly comparing different types of typhoid vaccines, we provide an indirect means of comparing the efficacy of different vaccines. The cumulative efficacy at 2.5 to 3 years for the Ty21a vaccine (three doses) and the Vi polysaccharide vaccine was 50% (95% CI 35% to 61%) and 55% (95% CI 30% to 70%), respectively. Both of these vaccines are widely used but are not immunogenic in children under two years old, which is a limitation. A recent systematic review into burden of enteric fever in children found contradictory evidence on the prevalence of typhoid fever in children under the age of five, with a suspected hidden burden, which may be multi‐factorial but includes diagnostic difficulties in this age group ([@CD001261-bbs2-0089]). The newer typhoid conjugate vaccines address this gap, as they are suitable to use in children under two years of age. The cumulative efficacy of the Vi‐rEPA vaccine at 3.8 years was higher (89%, 95% CI 76% to 97%), but this vaccine is unlicensed and has not been used commercially. Adverse events were mild in nature and, for the most part, were not significantly different between vaccine and placebo groups.

There is information on efficacy in Asia for each of the vaccines. There is limited data on efficacy of typhoid fever vaccination in Africa, with one trial in Egypt for Ty21a, [@CD001261-bbs2-0022], and one ViPs trial in South Africa, [@CD001261-bbs2-0007]. There is no information on efficacy of typhoid vaccination in sub‐Saharan Africa. There is evidence on efficacy for Ty21a in South America ([@CD001261-bbs2-0010]), but not for any of the other vaccines.

The newer typhoid conjugate vaccines Vi‐TT (PedaTyph and Typbar‐TCV) show promise in immunogenicity studies but as of yet efficacy data are only available for PedaTyph (two doses intramuscularly; [@CD001261-bbs2-0017]). In October 2017, the WHO\'s strategic advisory group of experts (SAGE) recommended Typbar‐TCV (1 dose intramuscularly; [@CD001261-bbs2-0061]) for children over six months in typhoid endemic countries ([@CD001261-bbs2-0122]), and in 2018 the WHO recommended this vaccine as the preferred choice for adults and children from six months to 44 years of age ([@CD001261-bbs2-0120]). In a human challenge setting Typbar‐TCV demonstrated similar levels of efficacy in healthy adults to ViPS ([@CD001261-bbs2-0050]), with higher rates of seroconversion and higher antibody GMTs in the conjugate vaccine group. At the time of writing, there were no efficacy data on Typbar‐TCV from field trials. Although promising, it is important to remember that human challenge studies are inherently small. In addition, the bacterial load and the timing of vaccination in relation to the challenge are highly controlled. These studies cannot replace large‐scale real‐life RCTs as sole evidence for approval of new vaccines but could be incorporated into a more efficient approval process. An RCT assessed Typbar‐TCV versus ViPS for immunogenicity and safety in people aged 2 to 45 years old ([@CD001261-bbs2-0061]). Infants and children aged 6 to 23 months were observed in a non‐controlled parallel trial. As there was no placebo control group, the trial could not assess adverse events from Typbar‐TCV, but these were reported as similar with TCV and ViPs, fever being the most common, with a single serious adverse event deemed unrelated to the vaccine. In an observational group of children under two years in the same study, authors again described adverse events as uncommon, with fever being the most usual ([@CD001261-bbs2-0061]).

From the evidence available we cannot comment on vaccine herd protection. As typhoid fever is spread faeco‐orally through contaminated food and water, it is plausible that if endemic populations began to routinely use the vaccines, intensity of transmission would be reduced due to a subsection of the population who were protected against infection ([@CD001261-bbs2-0090]). However, we did not find any studies describing the effect of vaccination on disease burden in the rest of the community.

Quality of the evidence {#CD001261-sec2-0012}
-----------------------

We assessed the certainty of evidence provided by the randomized studies using the GRADE approach, presenting our assessments in [Table 1](#CD001261-tbl-0001){ref-type="table"}, [Table 2](#CD001261-tbl-0002){ref-type="table"}, [Table 3](#CD001261-tbl-0003){ref-type="table"}, and [Table 4](#CD001261-tbl-0004){ref-type="table"}.

For the most widely used vaccines, oral Ty21a and ViPS, the evidence of benefit is of moderate certainty. A main limitation for us with Ty21a was the lack of cluster adjustment in trials using this method. For our meta‐analysis we estimated the effect of clustering, extrapolating from a ViPs trial where clustering was taken into account. For this reason we downgraded certainty to moderate. Although there is moderate unexplained heterogeneity in the 2.5 to 3 year cumulative efficacy of Ty21a, the CIs fall within a clinically important threshold, meaning the heterogeneity is unlikely be clinically significant.

For ViPs the certainty of evidence for efficacy in year 1 was high, but we downgraded it to moderate in the second year due to unexplained heterogeneity. Efficacy in year 3 and the 2.5‐year cumulative efficacy was low, but only one trial assessed longer follow‐up in South Africa in children aged 5 to 15. There was also imprecision as CIs were wide for both of these results.

The certainty of evidence for Vi‐rEPA was moderate, as there was a single trial, in one location (Vietnam) and only in children aged two to five.

Certainty of evidence for the new Vi‐TT vaccine is too limited to clearly make a recommendation for its adoption. The certainty of evidence for Vi‐TT (PedaTyph) is very low. There was lack of adjustment for cluster‐randomization and a risk of bias (funding by vaccine manufacturer, differing socioeconomic status between vaccine and control group, and selective outcome reporting). As the efficacy data is limited to one trial in children aged six months to 12 years in one location in India, we also downgraded the certainty of evidence for indirectness. The longer‐term protection for PedaTyph is still unknown, as only one‐year follow‐up data are available.

There were no serious adverse events reported for any of the vaccines, so we could not assess certainty of evidence.

Potential biases in the review process {#CD001261-sec2-0013}
--------------------------------------

We estimated an ICC for unadjusted cluster‐randomized trials that might not be precise. We did not conduct sensitivity analyses for the ICC, but we took a conservative approach and believe that the estimates are reasonable.

Diagnosis of typhoid fever remains a challenge, which may have affected the trial results for all of the vaccines. Our analysis for vaccine efficacy relies on blood‐culture positive typhoid fever; typhoid fever cases that are blood culture negative were missed. In one study the sensitivity of blood cultures compared to bone marrow cultures was only 66% ([@CD001261-bbs2-0105]). However, all of the trials that we included used positive blood culture for diagnosis of typhoid fever, and we did not exclude any trials on this basis of the efficacy outcome definition alone. Thus, we have presented the evidence as completely as possible.

None of the vaccines identified protect against *S.* Paratyphi A, the other 'typhoidal\' serovar of *Salmonella,* and most vaccine trials did not include outcomes for incidence of paratyphoid fever. Thus results reflect efficacy against typhoid fever caused by*S.* Typhi alone and do not reflect the overall efficacy against the disease in locations where *S.* Paratyphi*A* causes a significant number of cases.

We excluded human challenge studies as the bacterial inoculum in challenge trials is much higher and the timing of infection relative to vaccination is highly controlled compared to the real life situation, meaning the effect in real life is more difficult to extrapolate.This could have introduced bias against this vaccine because we had fewer data available for some of the newer vaccines, as human challenge studies provide results in a more time‐ and cost‐efficient manner compared to large scale implementation in RCTs. We are examining the methodological aspects of this approach of evaluating vaccines and how best to assess and present human challenge studies.

Agreements and disagreements with other studies or reviews {#CD001261-sec2-0014}
----------------------------------------------------------

No other systematic reviews were identified since the last publication of this review in 2014.

WHO recommends ViPS in people over two years old and oral Ty21a enteric capsules in people over six in areas with endemic typhoid fever and for outbreak control. This review provides evidence in support of this recommendation. The WHO recommends Vi‐TT Typbar‐TCV for infants and children over six months old in typhoid endemic with catch‐up vaccination where feasible ([@CD001261-bbs2-0120]). This review does not provide evidence for this recommendation, but it is likely that updates will when the ongoing studies investigating Vi‐TT Tybar‐TCV are completed ([@CD001261-bbs2-0083]; [@CD001261-bbs2-0084]; [@CD001261-bbs2-0085]).

Authors\' conclusions {#CD001261-sec1-0007}
=====================

Based on the available evidence from natural exposure, the currently licensed Ty21a and Vi polysaccharide vaccines are efficacious for preventing typhoid fever in children aged two years or older and in young adults living in typhoid‐endemic regions. Factors such as costs, availability and convenience of administration may determine which vaccine is chosen for use.We are uncertain of the effects of Vi‐TT on typhoid fever, and further data are needed to assess PedaTyph and Typbar‐TCV efficacy in adults and children evaluated through natural exposure. The recent approval of conjugate typhoid vaccine Typbar‐TCV for use in endemic countries by the WHO and SAGE; together with the formation of the Typhoid Vaccine Acceleration Consortium (TyVAC); results of some seroefficacy studies ([@CD001261-bbs2-0075]); and the pending results of Typbar‐TCV RCTs currently being conducted in Malawi ([@CD001261-bbs2-0085]), Nepal ([@CD001261-bbs2-0084]), and Bangladesh ([@CD001261-bbs2-0083]), will help establish the firm knowledge base required for the introduction of typhoid conjugate vaccines to endemic countries ([@CD001261-bbs2-0060]).An effective typhoid vaccine is still needed for children under two years of age. The new Vi‐TT vaccines are promising; however, at present there was only one trial available, which we judged to have very low certainty‐evidence. Further efficacy data are pending and are likely to change this certainty when available. Neither the Vi polysaccharide vaccine nor the Ty21a vaccine is licensed for children younger than two years of age. Future trials should be sufficiently powered to present results stratified by age group. This would mean that vaccine efficacy in different groups could be analysed and would ensure that vaccine delivery can be targeted appropriately (for example, via a school‐based programme or through the expanded programme of immunization (EPI)).None of the included trials compared different types of vaccines used to prevent typhoid fever. Such future comparisons may be helpful in allowing direct conclusions regarding the relative efficacy of the vaccines, although such evidence would not necessarily promote the introduction of vaccines against typhoid fever to new settings and would require substantial resources.Future trials should conduct analyses suited to their design; cluster‐randomization should be accounted for in sample size calculations and in analyses of results.
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^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane.

Serious adverse effects {#CD001261-sec3-0047}
=======================

**TrialTy21a vaccineControlEventsPeople vaccinatedEventsPeople vaccinatedEnteric capsules**[@CD001261-bbs2-0008]01720367[@CD001261-bbs2-0020]03110291Subtotal04830658**Liquid formulation**[@CD001261-bbs2-0018]088082[@CD001261-bbs2-0019]03330255[@CD001261-bbs2-0022]016486015902[@CD001261-bbs2-0023]04130417Subtotal0173200116656**In milk with sodium bicarbonate**[@CD001261-bbs2-0009]01650172Subtotal01650172Total0179680117486

Ty21a adverse events per dose of vaccine (cluster unadjusted) {#CD001261-sec3-0048}
=============================================================

**Adverse eventTrialVaccine events/total (%)Placebo events/total (%)**Vomiting[@CD001261-bbs2-0022]49/47037 (0.1%)21/45638 (0.05%)[@CD001261-bbs2-0023]12/1159 (1.04%)2/1311 (0.15%)Fever[@CD001261-bbs2-0022]1/47037 (0.002%)3/45638 (0.07%)[@CD001261-bbs2-0023]1/1159 (0.01%)1/1311 (0.08%)Nausea/\
abdominal pain[@CD001261-bbs2-0022]14/47037 (0.03%)2/45638 (0.004%)[@CD001261-bbs2-0023]3/1159 (0.26%)0/1311 (0%)

Comparison 1Ty21a vaccine (3 doses) versus control: efficacyOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Incidence of typhoid fever, year 1](#CD001261-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever, year 1.476296Risk Ratio (M‐H, Random, 95% CI)0.55 \[0.35, 0.86\][2 Incidence of typhoid fever, year 2](#CD001261-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 2 Incidence of typhoid fever, year 2.476296Risk Ratio (M‐H, Random, 95% CI)0.41 \[0.29, 0.57\][3 Incidence of typhoid fever, year 3](#CD001261-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 3 Incidence of typhoid fever, year 3.476296Risk Ratio (M‐H, Random, 95% CI)0.44 \[0.25, 0.76\][4 Cumulative incidence of typhoid fever at 2.5 to 3 years](#CD001261-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 4 Cumulative incidence of typhoid fever at 2.5 to 3 years.9235239Risk Ratio (M‐H, Random, 95% CI)0.50 \[0.39, 0.65\]

Comparison 2Ty21a vaccine: liquid formulation versus enteric capsules (3 doses)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Cumulative incidence of typhoid fever at 2.5 to 3 years](#CD001261-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Ty21a vaccine: liquid formulation versus enteric capsules (3 doses), Outcome 1 Cumulative incidence of typhoid fever at 2.5 to 3 years.280127Risk Ratio (M‐H, Random, 95% CI)0.54 \[0.24, 1.23\]

Comparison 3Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 yearsOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Incidence of typhoid fever](#CD001261-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 years, Outcome 1 Incidence of typhoid fever.2Risk Ratio (M‐H, Random, 95% CI)Subtotals only

Comparison 4Ty21a vaccine versus control: adverse eventsOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Fever](#CD001261-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 1 Fever.42066Risk Ratio (M‐H, Random, 95% CI)1.84 \[1.02, 3.31\][2 Vomiting](#CD001261-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 2 Vomiting.42066Risk Ratio (M‐H, Random, 95% CI)1.15 \[0.43, 3.05\][3 Diarrhoea](#CD001261-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 3 Diarrhoea.42066Risk Ratio (M‐H, Random, 95% CI)0.80 \[0.52, 1.24\][4 Nausea or abdominal pain](#CD001261-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 4 Nausea or abdominal pain.4Risk Ratio (M‐H, Random, 95% CI)Subtotals only4.1 Enteric capsules21141Risk Ratio (M‐H, Random, 95% CI)2.92 \[1.53, 5.57\]4.2 Liquid formulation1588Risk Ratio (M‐H, Random, 95% CI)1.84 \[0.90, 3.77\]4.3 In milk with sodium bicarbonate1337Risk Ratio (M‐H, Random, 95% CI)0.66 \[0.39, 1.13\][5 Headache](#CD001261-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 5 Headache.21190Risk Ratio (M‐H, Random, 95% CI)1.31 \[0.76, 2.27\][6 Rash](#CD001261-fig-00406){ref-type="fig"}Analysis 4.6Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 6 Rash.21190Risk Ratio (M‐H, Random, 95% CI)2.94 \[0.61, 14.12\][7 Any mild adverse event](#CD001261-fig-00407){ref-type="fig"}Analysis 4.7Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 7 Any mild adverse event.31360Risk Ratio (M‐H, Random, 95% CI)1.67 \[1.03, 2.72\]

Comparison 5Vi polysaccharide vaccine (1 dose) versus control: efficacyOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Incidence of typhoid fever](#CD001261-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Vi polysaccharide vaccine (1 dose) versus control: efficacy, Outcome 1 Incidence of typhoid fever.6Risk Ratio (Random, 95% CI)Subtotals only1.1 Year 1399797Risk Ratio (Random, 95% CI)0.31 \[0.26, 0.37\]1.2 Year 24194969Risk Ratio (Random, 95% CI)0.41 \[0.31, 0.55\]1.3 Year 3111384Risk Ratio (Random, 95% CI)0.50 \[0.32, 0.78\][2 Cumulative incidence of typhoid fever at 2.5 to 3 years](#CD001261-fig-00502){ref-type="fig"}Analysis 5.2Comparison 5 Vi polysaccharide vaccine (1 dose) versus control: efficacy, Outcome 2 Cumulative incidence of typhoid fever at 2.5 to 3 years.111384Risk Ratio (M‐H, Random, 95% CI)0.45 \[0.30, 0.70\]

Comparison 6Vi polysaccharide vaccine versus control: adverse eventsOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Fever](#CD001261-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 1 Fever.4133038Risk Ratio (M‐H, Random, 95% CI)0.98 \[0.85, 1.14\][2 Erythema](#CD001261-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 2 Erythema.3132261Risk Ratio (M‐H, Random, 95% CI)3.04 \[0.45, 20.30\][3 Swelling at injection site](#CD001261-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 3 Swelling at injection site.31767Risk Ratio (M‐H, Random, 95% CI)6.06 \[1.07, 34.22\][4 Pain at injection site](#CD001261-fig-00604){ref-type="fig"}Analysis 6.4Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 4 Pain at injection site.1667Risk Ratio (M‐H, Random, 95% CI)7.98 \[3.69, 17.24\][5 Serious adverse events](#CD001261-fig-00605){ref-type="fig"}Analysis 6.5Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 5 Serious adverse events.4133038Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\]

Comparison 7Vi‐rEPA (2 doses) versus control: efficacyOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Incidence of typhoid fever](#CD001261-fig-00701){ref-type="fig"}Analysis 7.1Comparison 7 Vi‐rEPA (2 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever.1Risk Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Year 1112008Risk Ratio (M‐H, Random, 95% CI)0.06 \[0.01, 0.25\]1.2 Year 2112008Risk Ratio (M‐H, Random, 95% CI)0.13 \[0.04, 0.44\]1.3 Cumulative 2 years112008Risk Ratio (M‐H, Random, 95% CI)0.09 \[0.04, 0.22\]1.4 Cumulative 46 months112008Risk Ratio (M‐H, Random, 95% CI)0.11 \[0.05, 0.23\]

Comparison 8Vi‐rEPA vaccine versus control: adverse eventsOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Fever after Vi‐rEPA (dose1)](#CD001261-fig-00801){ref-type="fig"}Analysis 8.1Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 1 Fever after Vi‐rEPA (dose1).112008Risk Ratio (M‐H, Random, 95% CI)2.54 \[1.69, 3.82\][2 Fever after Vi‐rEPA (dose 2)](#CD001261-fig-00802){ref-type="fig"}Analysis 8.2Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 2 Fever after Vi‐rEPA (dose 2).111091Risk Ratio (M‐H, Random, 95% CI)4.39 \[2.85, 6.77\][3 Erythema after Vi‐rEPA (dose 1)](#CD001261-fig-00803){ref-type="fig"}Analysis 8.3Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 3 Erythema after Vi‐rEPA (dose 1).112008Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\][4 Erythema after Vi‐rEPA (dose 2)](#CD001261-fig-00804){ref-type="fig"}Analysis 8.4Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 4 Erythema after Vi‐rEPA (dose 2).111091Risk Ratio (M‐H, Random, 95% CI)2.01 \[0.18, 22.21\][5 Swelling at injection site after Vi‐rEPA (dose 1)](#CD001261-fig-00805){ref-type="fig"}Analysis 8.5Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 5 Swelling at injection site after Vi‐rEPA (dose 1).112008Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\][6 Swelling at injection site after Vi‐rEPA (dose 2)](#CD001261-fig-00806){ref-type="fig"}Analysis 8.6Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 6 Swelling at injection site after Vi‐rEPA (dose 2).111091Risk Ratio (M‐H, Random, 95% CI)20.15 \[2.71, 150.08\][7 Serious adverse events](#CD001261-fig-00807){ref-type="fig"}Analysis 8.7Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 7 Serious adverse events.112008Risk Ratio (M‐H, Random, 95% CI)0.0 \[0.0, 0.0\]

Comparison 9Vi‐TT vaccine Peda Typh (2 doses) versus control: efficacyOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Incidence of typhoid fever, Year 1](#CD001261-fig-00901){ref-type="fig"}Analysis 9.1Comparison 9 Vi‐TT vaccine Peda Typh (2 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever, Year 1.11353Risk Ratio (M‐H, Random, 95% CI)0.06 \[0.00, 1.01\]

**DateEventDescription**3 May 2018New citation required and conclusions have changedThis review update includes one new trial, evaluating the Vi‐polysaccharide tetanus‐toxoid conjugate vaccine (Vi‐TT PedaTyph).6 March 2018New search has been performedThis is an update of [@CD001261-bbs2-0123] with a new search up to 14 February 2018. We have updated the [Background](#CD001261-sec1-0002){ref-type="sec"} and adjusted the protocol to make clear that the review does not include human challenge studies. We also updated the protocol to exclude adverse effects comparison trials using non‐placebo vaccines as a control. We updated our methods to include in the meta‐analysis cluster‐randomized trials that we had previously described in separate tables.

Protocol first published: Issue 4, 1998 Review first published: Issue 4, 1998

**DateEventDescription**17 June 2013New citation required but conclusions have not changedFour new trials added.17 June 2013New search has been performedThis is an update of the review prepared by Fraser et al ([@CD001261-bbs2-0126]). This review update includes four new trials, three evaluating the Vi polysaccharide vaccine (two reporting on efficacy and adverse events, one reporting on adverse events only) and one evaluating the Vi‐rEPA vaccine (reporting adverse events).22 August 2008AmendedConverted to new review format with minor editing.26 April 2007New citation required and conclusions have changed2007, Issue 3: This review is an update of the original version prepared by EA Engels and J Lau ([@CD001261-bbs2-0124]). This review evaluates the evidence available for a new vaccine (Vi‐rEPA) and includes 3 new efficacy trials that were not included in Engels 1998a (1 evaluating the Vi‐rEPA and 2 evaluating the Vi polysaccharide vaccine). It would also have included head‐on comparisons of the different types of vaccines (not included in [@CD001261-bbs2-0124]) had these direct comparisons been conducted. Since [@CD001261-bbs2-0124] was published, killed whole‐cell vaccines are no longer in use and therefore are not included in this review.

In this update, we excluded trials that reported on adverse events where typhoid vaccines were compared to an alternative vaccine rather than placebo. This is because other vaccines may also have adverse events associated with them -- such as fever or erythema at injection site -- and would not enable a true assessment of adverse events associated with typhoid vaccines. We excluded human challenge trials; this had not been explicitly stated in the protocol but none were included in the previous review.

Characteristics of included studies \[ordered by study ID\] {#CD001261-sec2-0019}
===========================================================

[@CD001261-bbs2-0001]MethodsDesign: individual‐RCT\
Active surveillance for efficacy (health workers visited vaccinees every 2 days; in case of a fever lasting longer than 3 days, a blood sample was taken) and adverse events (health workers examined vaccinees on days 1 to 3 postvaccination)ParticipantsNumber: 6907\
Inclusion criteria: age 5 to 44 years\
Exclusion criteria: children age \< 2 years; fever or acute illness; pregnancyInterventionsCapsular polysaccharide of *S.* Typhi*,* Vi: 25 µg Vi in 0.5 mL; 3457 participantsPneumococcal vaccine: 25 µg; 3450 participants\
Route and schedule: intramuscular injection; 1 dose\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Adverse eventsNotesLocation: 5 villages near Kathmandu, Nepal\
Socioeconomic description: rural, low income\
Setting: home\
Date: 1986 to 1988\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomized, random arrangement of syringes in packages of 10. Insufficient information about the sequence generation process provided to permit judgementAllocation concealment (selection bias)Low riskSequentially numbered vaccines of identical appearanceBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind trialIncomplete outcome data (attrition bias) All outcomesLow riskInclusion of randomized assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll expected outcomes reported onOther biasLow riskNone[@CD001261-bbs2-0002]MethodsDesign: cluster‐RCT (classroom)\
Intermediate surveillance for efficacy: enteric fever and isolation of *S.* Typhi from blood or bone marrow in clinics and local hospital during the study (5‐year follow‐up)ParticipantsNumber: 54,925 participants\
Number of classrooms: 3655\
Inclusion criteria: age 5 to 22 years\
Exclusion criteria: no detailsInterventionsLyophilized attenuated *S.* Typhi strain Ty21a: enteric‐coated capsule containing 2‐5 × 10^9^ viable Ty21a; 27,620 participantsPlacebo: in enteric‐coated capsule; 27,305 participants\
Route and schedule: oral; 2 doses, 1 week apart\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia or in bone marrow)NotesLocation: northern area of Santiago, Chile\
Socioeconomic description: no details\
Setting: school\
Date: 1982 to 1987\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Low riskAllocation concealment: central (WHO). Sequentially numbered vaccines of identical appearanceBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blindIncomplete outcome data (attrition bias) All outcomesUnclear riskOf 91,954 participating children, 82,543 received all assigned doses. No reason for missing data providedSelective reporting (reporting bias)Low riskAll expected outcomes reported onOther biasUnclear riskUnclear whether data were adjusted for clustering[@CD001261-bbs2-0003]MethodsParticipantsInterventionsLyophilized attenuated *S.* Typhi strain Ty21a: enteric‐coated capsule containing 2‐5 × 10^9^ viable Ty21a; 27,618 participantsPlacebo: in enteric‐coated capsule; 27,305 participants\
Route and schedule: oral; 1 dose (2nd dose contained placebo in all participants)\
Concomitant medication: not specifiedOutcomesNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Allocation concealment (selection bias)Low riskBlinding (performance bias and detection bias) All outcomesLow riskSelective reporting (reporting bias)Low risk[@CD001261-bbs2-0004]MethodsDesign: individual‐RCTParticipantsNumber: 634\
Inclusion criteria: children 2 to 6 years old with no history of typhoid fever\
Exclusion criteria: no detailsInterventionsTy21a liquid formulationPlacebo\
Route and schedule: oral solution; 3 dosesOutcomesAdverse eventsImmunogenicityNotesLocation: Thailand\
Socioeconomic description: no details\
Date: no details\
No demographic details***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of the allocation sequence: unclearAllocation concealment (selection bias)Low riskSequentially numbered vaccines of identical appearanceBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blindIncomplete outcome data (attrition bias) All outcomesHigh riskNumber of participants per study arm not specifiedSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgementOther biasLow riskNone[@CD001261-bbs2-0005]MethodsDesign: individually based RCT\
Active surveillance for adverse events: local and systemic symptoms before and at 24 and 48 hours after inoculation; fever and symptoms at 6 to 9 hours, days 1, 2, 7, 14 and 28 after inoculationParticipantsNumber: 323\
Inclusion criteria: age 8 to 40 years; healthy; no previous typhoid vaccination\
Exclusion criteria: no detailsInterventionsCapsular polysaccharide of *S.* Typhi, Vi vaccine (freeze‐dried preparation and liquid preparation): 25 µg Vi in 0.5 mL; 237 participantsPlacebo: 86 participants\
Route and schedule: intramuscular injection; 1 dose\
Concomitant medication: not specifiedOutcomesAdverse eventsImmunogenicityNotesLocation: Houston, Texas, USA\
Socioeconomic description: urban, high income\
Setting: clinic\
Date: no information\
No demographic information\
Results presented jointly for 3 separate trials***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Unclear riskAllocation concealment: unclearBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blindIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomly assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll outcomes reported onOther biasLow riskNone[@CD001261-bbs2-0006]MethodsDesign: cluster‐RCT (geographic clusters)\
Intermediate surveillance for efficacy: participants were identified through 3 study health centres during study period (2 years)\
Surveillance for adverse events: all participants were visited 30 minutes after vaccination; a subgroup of 240 participants were visited 3 days after vaccination, and an adverse event form was completedParticipants51,965 participants\
120 geographic clusters using the geographic information system (GIS) imagery (60 clusters in each study arm)\
Inclusion criteria: children between the ages of 2 and 16 years\
Exclusion criteria: married female children older than 12 years of age were not included to avoid inadvertent immunization of pregnant women. Recent history of feverInterventionsSingle‐dose capsular polysaccharide of *S.* Typhi, Vi vaccine (dose 25 mcg)Hepatitis A vaccine (dose 720 IU)\
Route and schedule: single intramuscular injection, Vi vaccine or hepatitis A vaccineOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Indirect protection from typhoid feverAdverse eventsNotesLocation: Karachi, Pakistan\
Socioeconomic description: low‐socioeconomic urban squatter settlements\
Date: 2002 and 2007\
Setting: vaccination centres and health centres***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskA table of random numbers was usedAllocation concealment (selection bias)Low riskVaccine identified by code, code assignment held centrallyBlinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators blinded -- vaccines identified only by code. One vaccine administered per clusterIncomplete outcome data (attrition bias) All outcomesLow riskReason for missing data given (migration, dying from other causes) and balanced across groupsSelective reporting (reporting bias)Low riskStudy protocol not available but published study reports on both primary and secondary outcomeOther biasLow riskNo recruitment bias, no baseline imbalance, no loss of clusters, analysis adjusted for clustering using generalized estimating equation[@CD001261-bbs2-0007]MethodsDesign: individually based RCT\
Active surveillance for efficacy: blood cultures if febrile with no obvious clinical causeParticipantsNumber: 11,384\
Inclusion criteria: 5 to 15 years\
Exclusion criteria: no detailsInterventionsCapsular polysaccharide of *S.* Typhi, Vi vaccine: 25 µg Vi; 5692 participantsMeningococcal vaccine: 25 µg Vi; 5692 participants\
Route and schedule: intramuscular injection; 1 dose\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)ImmunogenicityNotesLocation: eastern Transvaal area of South Africa\
Socioeconomic description: no details\
Setting: school\
Date: 1985 to 1988\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomization process unclearAllocation concealment (selection bias)Low riskSequentially numbered vaccines of identical appearance. Code held by independent observersBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind. Vaccines identical in appearanceIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomized assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasLow riskNone[@CD001261-bbs2-0008]MethodsDesign: individually based RCT\
Active surveillance for adverse events: no further detailsParticipantsNumber: 539\
Inclusion criteria: adults, no details\
Exclusion criteria: no detailsInterventionsEnteric‐coated capsules *S.* Typhi Ty21a vaccine: 172 participantsPlacebo: 367 participants\
Route and schedule: oral capsules; 3 doses\
Concomitant medication: not specifiedOutcomesAdverse eventsNotesLocation: Chile\
Socioeconomic description: no details\
Setting: no details\
Date: no details\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Unclear riskAllocation concealment: unclearBlinding (performance bias and detection bias) All outcomesLow riskBlinding: double‐blind (no details)Incomplete outcome data (attrition bias) All outcomesUnclear riskInclusion of randomly assigned participants in analysis: unclearSelective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasLow riskNone[@CD001261-bbs2-0009]MethodsSee [@CD001261-bbs2-0008] ([@CD001261-bbs2-0009] is a different arm of the same trial with separate placebo group)ParticipantsNumber: 337\
Inclusion criteria: children, no details\
Exclusion criteria: no detailsInterventions*S.* Typhi Ty21a vaccine in milk with NaHCO3S: 172 participantsPlacebo: 172 participants\
Route and schedule: oral capsules; 3 doses\
Concomitant medication: not specifiedOutcomesDetails as for [@CD001261-bbs2-0008]NotesDetails as for [@CD001261-bbs2-0008]***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDetails as for [@CD001261-bbs2-0008]Allocation concealment (selection bias)Unclear riskDetails as for [@CD001261-bbs2-0008]Blinding (performance bias and detection bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0008]Incomplete outcome data (attrition bias) All outcomesUnclear riskDetails as for [@CD001261-bbs2-0008]Selective reporting (reporting bias)Low riskDetails as for [@CD001261-bbs2-0008]Other biasLow riskDetails as for [@CD001261-bbs2-0008][@CD001261-bbs2-0010]MethodsDesign: cluster‐RCT (classroom)\
Intermediate surveillance for efficacy: enteric fever and isolation of *S.* Typhi from blood, bone marrow or bile‐stained duodenal fluid in the hospital or in clinics during the trial (3 years)ParticipantsNumber: 27,074\
Number of classrooms: 4312\
Inclusion criteria: age 6 to 21 years; parental consent; no further details\
Exclusion criteria: no detailsInterventionsEnteric capsules of *S.* Typhi, Ty21a vaccine: 21,598 participantsPlacebo: 5476 participants (placebo group divided into 4 equal groups for the comparison)\
Route and schedule: oral capsules; 3 doses given 21 days apart\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia, in bone marrow or in duodenal fluid)NotesLocation: Chile socioeconomic description: no details\
Setting: school\
Date: 1983 to 1986\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Low riskSequentially numbered vaccines of identical appearanceBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blindIncomplete outcome data (attrition bias) All outcomesUnclear riskInclusion of randomly assigned participants in analysis: 78% (109,594/141,127) of enrolled children received 3 doses and included in results. No reason for missing data givenSelective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasUnclear riskAnalysis not adjusted for clustering[@CD001261-bbs2-0011]MethodsSee [@CD001261-bbs2-0010] ([@CD001261-bbs2-0011] is a different arm of the same trial)\
Details as for [@CD001261-bbs2-0010], except blinding: placebo given in a similar regimen, but not mentioned if identical to gelatin or enteric capsulesParticipantsDetails as for [@CD001261-bbs2-0010], except number: 27,647InterventionsEnteric capsules of *S.* Typhi, Ty21a vaccine: 22,170 participantsPlacebo: 5477 participants (placebo group divided into 4 equal groups for the comparison)\
Route and schedule: oral capsules; 3 doses given 2 days apart Concomitant medication: not specifiedOutcomesDetails as for [@CD001261-bbs2-0010]NotesDetails as for [@CD001261-bbs2-0010]***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDetails as for [@CD001261-bbs2-0010]Allocation concealment (selection bias)Low riskDetails as for [@CD001261-bbs2-0010]Blinding (performance bias and detection bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0010]Incomplete outcome data (attrition bias) All outcomesUnclear riskDetails as for [@CD001261-bbs2-0010]Selective reporting (reporting bias)Low riskDetails as for [@CD001261-bbs2-0010]Other biasUnclear riskDetails as for [@CD001261-bbs2-0010][@CD001261-bbs2-0012]MethodsSee [@CD001261-bbs2-0010] ([@CD001261-bbs2-0012] is a different arm of the same trial)ParticipantsDetails as for [@CD001261-bbs2-0010], except number: 27,017InterventionsDetails as for [@CD001261-bbs2-0010], except:\
Gelatin capsules of *S.* Typhi, Ty21a vaccine: 21,541Placebo: 5476 (placebo group divided into 4 equal groups for the comparison)OutcomesDetails as for [@CD001261-bbs2-0010]NotesDetails as for [@CD001261-bbs2-0010]***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDetails as for [@CD001261-bbs2-0010]Allocation concealment (selection bias)Low riskDetails as for [@CD001261-bbs2-0010]Blinding (performance bias and detection bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0010]Incomplete outcome data (attrition bias) All outcomesUnclear riskDetails as for [@CD001261-bbs2-0010]Selective reporting (reporting bias)Low riskDetails as for [@CD001261-bbs2-0010]Other biasUnclear riskDetails as for [@CD001261-bbs2-0010][@CD001261-bbs2-0013]MethodsSee [@CD001261-bbs2-0010] ([@CD001261-bbs2-0013] is a different arm of the same trial)\
Details as for [@CD001261-bbs2-0010], except blinding: placebo given in a similar regimen, but not mentioned whether identical to gelatin or enteric capsulesParticipantsDetails as for [@CD001261-bbs2-0010], except number: 27,856InterventionsGelatin capsules of *S.* Typhi, Ty21a vaccine: 22,379 participantsPlacebo: 5477 participants (placebo group divided into 4 equal groups for the comparison)\
Route and schedule: oral capsules; 3 doses given 2 days apart\
Concomitant medication: not specifiedOutcomesDetails as for [@CD001261-bbs2-0010]NotesDetails as for [@CD001261-bbs2-0010]***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDetails as for [@CD001261-bbs2-0010]Allocation concealment (selection bias)Low riskDetails as for [@CD001261-bbs2-0010]Blinding (performance bias and detection bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0010]Incomplete outcome data (attrition bias) All outcomesUnclear riskDetails as for [@CD001261-bbs2-0010]Selective reporting (reporting bias)Low riskDetails as for [@CD001261-bbs2-0010]Other biasUnclear riskDetails as for [@CD001261-bbs2-0010][@CD001261-bbs2-0014]MethodsDesign: cluster‐RCT (classroom)\
Intermediate surveillance for efficacy: enteric fever and isolation of *S.* Typhi from blood, bone marrow or bile‐stained duodenal fluid in the hospital or in clinics during the study (5 years)ParticipantsNumber: 42,073\
Number of classes: 5423\
Inclusion criteria: 5 to 19 years old; parental consent; no further details\
Exclusion criteria: no detailsInterventionsLiquid formulation of *S.* Typhi, Ty21a vaccine: 36,623 participantsPlacebo: 5450 participants\
Route and schedule: oral solution; 3 doses given 2 days apart\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia, in bone marrow or in duodenal fluid)NotesLocation: Chile\
Socioeconomic description: no details\
Setting: school\
Date: 1986 to 1991\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Low riskSequentially numbered vaccines of identical appearance. Code kept at WHOBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind. Identical packets and capsulesIncomplete outcome data (attrition bias) All outcomesUnclear riskInclusion of randomly assigned participants in analysis: 85% (81,621/95,910 children who received at least 1 dose) received all 3 doses and included in results. No reason for missing data givenSelective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasUnclear riskAnalysis not adjusted for clustering; however, authors state, \"analysis of cases by class after three years of follow‐up showed no clustering\"[@CD001261-bbs2-0015]MethodsSee [@CD001261-bbs2-0014] ([@CD001261-bbs2-0015] is a different arm of the same trial)\
Details as for [@CD001261-bbs2-0014], except intermediate surveillance for efficacy for 3 yearsParticipantsDetails as for [@CD001261-bbs2-0014], except number: 39,548InterventionsDetails as for [@CD001261-bbs2-0014], except:\
Enteric capsules of *S.* Typhi, Ty21a vaccine: 34,696 participantsPlacebo: 4852 participantsOutcomesDetails as for [@CD001261-bbs2-0014]NotesDetails as for [@CD001261-bbs2-0014]***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDetails as for [@CD001261-bbs2-0014]Allocation concealment (selection bias)Low riskDetails as for [@CD001261-bbs2-0014]Blinding (performance bias and detection bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0014]Incomplete outcome data (attrition bias) All outcomesUnclear riskDetails as for [@CD001261-bbs2-0014]Selective reporting (reporting bias)Low riskDetails as for [@CD001261-bbs2-0014]Other biasUnclear riskDetails as for [@CD001261-bbs2-0014][@CD001261-bbs2-0016]MethodsDesign: individually based RCT\
Active surveillance for efficacy and adverse events: weekly history; temperature; blood cultures and serology if febrile during the trial (27 months); review of bacteriological records in the provincial hospital\
Passive surveillance: 19 additional monthsParticipantsNumber: 12,008\
Inclusion criteria: age 2 to 5 years; no further details\
Exclusion criteria: illnesses that required ongoing medical care; fever \> 37.5°C at first injectionInterventionsVi‐rEPA vaccine; capsular polysaccharide of *S.* Typhi, Vi, bound to a nontoxic recombinant protein that is antigenically identical to *Pseudomonas aeruginosa* exotoxin A; 22 µg Vi in 0.5 mL; 5991 participantsPlacebo: 6017 participants\
Route and schedule: intramuscular injection; 2 doses, 6 weeks apart\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Adverse eventsImmunogenicity\
Subgroups for gender, age and study yearNotesLocation: Dong Thap Province, Mekong Delta, Vietnam\
Socioeconomic description: rural; low income\
Setting: home\
Date: 1998 to 2000\
Sex, age at vaccination, household composition and size and interval between the 2 injections similar in both groups***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskIdentical looking vaccine and placebo were randomly numbered 0 to 9 and packaged in packets of 10; however, unclear how randomization sequence generatedAllocation concealment (selection bias)Low riskCode identifying identical‐looking vaccine and placebo was kept at the central pharmacyBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind. Vaccine and placebo vials indistinguishableIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomly assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll expected outcomes reported onOther biasLow riskNone[@CD001261-bbs2-0017]MethodsDesign: open label, cluster‐RCT (school)\
12 months active follow‐up: weekly telephone follow‐up, monthly social worker follow‐up in school, school absenteeism record and subject diary kept by parent (collected after 12 months)ParticipantsNumber: 1765\
Inclusion criteria: children 6 months to 12 years old. 12 schools in 2 municipal wards in Kolkata, India. Voluntary written informed consent from parent/guardian.\
Siblings of school children aged 6 months to 3 years were also invited.\
Exclusion criteria: fever \> 38.5°C at time of enrolment or history of undiagnosed fever/infection of more than 3 days duration within 1 month prior to vaccination, established or clinically suspected immunosuppressive or immune compromised disorder/state (congenital or acquired drug induced, neoplastic, TB etc), anyone who had a typhoid vaccination in the last 3 years and with a known allergy to any of the components in PedaTyphInterventionsPedaTyph (test group): containing 5micrograms of Vi polysaccharide of S. Typhi conjugated to 5 µg of tetanus toxoid (Vi‐TT): 905 participantsNormal vaccination course (control): 860 participants\
Route and administration: 2 doses of PedaTyph vaccine 0.5 mL administered intramuscularly in the upper arm with a 6 week interval between doses\
Concomitant medication: not specifiedOutcomesMicrobiologically proven (BACTEC positive) Typhoid feverImmunogenicityAdverse effects at 30 minutes, 1 month and clinical events up to 12 months (observational as no placebo comparison)NotesLocation: Kolkata, India\
Socioeconomic description: low income, urban\
Setting: school\
Date: no details***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStatistician used graph pad software to generate random numbers to assign clusters to vaccine and control groupAllocation concealment (selection bias)Low riskAllocation by a statistician who was blinded as to clustersBlinding (performance bias and detection bias) All outcomesHigh riskOpen label -- no placeboIncomplete outcome data (attrition bias) All outcomesLow risk6 lost to follow‐up in test group due to moving out of area. Although 140 patients in the test group did not get the second dose of the vaccine they were all followed upSelective reporting (reporting bias)High riskParatyphoid cases were not reported (as was intended in the protocol registered prospectively).Other biasHigh riskAccording to prospectively published protocol, funding was by the company who manufacturers the Peda Typh vaccine (no mention of this in the published trial)\
The intervention and the control group were very different in terms of socioeconomic status, with lower status in the control group.\
The trial results were unadjusted for cluster randomization.[@CD001261-bbs2-0018]MethodsDesign: individually based RCT\
Active surveillance for adverse events: 1.5 hours of observation and parental reporting via adverse event report sheetParticipantsNumber: 170\
Inclusion criteria: age 4 to 6 years; no further details\
Exclusion criteria: no detailsInterventionsLiquid formulation of *S.* Typhi, TY21a: 88 participantsPlacebo: 82 participants\
Route and schedule: oral solution; 3 doses, alternate days\
Concomitant medication: not specifiedOutcomesAdverse eventsImmunogenicityNotesLocation: Thailand\
Socioeconomic description: no details\
Setting: clinic\
Date: no details\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: not mentionedAllocation concealment (selection bias)Unclear riskAllocation concealment: no informationBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind. Identical vaccine and placebo packagesIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomly assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasLow riskNone[@CD001261-bbs2-0019]MethodsDesign: individually based RCT\
Intermediate surveillance for efficacy: isolation of *S.* Typhi from blood during trial (2.5 years)\
Surveillance for adverse events: questionnaires collected from 588 individualsParticipantsNumber: 10,212\
Inclusion criteria: age 3 to 44 years; no further details\
Exclusion criteria: pregnant women; febrile illnessInterventionsLiquid formulation of *S.* Typhi, Ty21a: 5066 participantsPlacebo: 5146 participants\
Route and schedule: oral solution; 3 doses, 1 week apart\
Concomitant medication: not specified\
Note [@CD001261-bbs2-0020] is 2 different arms of the same trial (see below for further details). [@CD001261-bbs2-0019] and [@CD001261-bbs2-0020] had different placebo groupsOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Adverse events\
Subgroups for age and study yearNotesLocation: Plaju and Sungai Gerong, Sumatra, Indonesia\
Socioeconomic description: no details\
Setting: clinic\
Date: 1986 to 1989\
Sex, age at vaccination, residence in a compound, history of typhoid vaccination and level of education similar in both groups***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskGeneration of allocation sequence: computer‐generated table of random numbersAllocation concealment (selection bias)Low riskIdentical vaccine and placeboBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind. Identical vaccine and placeboIncomplete outcome data (attrition bias) All outcomesLow risk93% of participants (20,543/22,001) received 3 doses and included in results. Missing outcome data balanced across intervention and control groupsSelective reporting (reporting bias)Low riskAll expected outcomes reported onOther biasLow riskNone[@CD001261-bbs2-0020]MethodsSee [@CD001261-bbs2-0019] ([@CD001261-bbs2-0020] is a different arm of the same trial)\
Details as for [@CD001261-bbs2-0014], except surveillance for adverse events: questionnaires collected from 602 individualsParticipantsDetails as for [@CD001261-bbs2-0019], except number: 10,331InterventionsEnteric capsules of *S.* Typhi, Ty21a: 5209 participantsPlacebo: 5122 participants\
Route and schedule: oral capsules; 3 doses, 1 week apart Concomitant medication: not specified\
Note [@CD001261-bbs2-0019] is two different arms of the same trial (see above for further details). [@CD001261-bbs2-0019] and [@CD001261-bbs2-0020] had different placebo groupsOutcomesDetails as for [@CD001261-bbs2-0019]NotesDetails as for [@CD001261-bbs2-0019]***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskDetails as for [@CD001261-bbs2-0019]Allocation concealment (selection bias)Low riskDetails as for [@CD001261-bbs2-0019]Blinding (performance bias and detection bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0019]Incomplete outcome data (attrition bias) All outcomesLow riskDetails as for [@CD001261-bbs2-0019]Selective reporting (reporting bias)Low riskDetails as for [@CD001261-bbs2-0019]Other biasLow riskDetails as for [@CD001261-bbs2-0019][@CD001261-bbs2-0021]MethodsDesign: cluster‐RCT (geographic clusters)\
Active surveillance for efficacy: 5 study clinics were established to conduct surveillance for febrile illnesses and to refer participants with severe disease for hospital care during study period (2 years)\
Surveillance period adverse events: all participants 30 minutes after vaccination, subgroup of 320 participants for 3 consecutive days, passive surveillance for adverse events for 1 month at all study clinics and hospitalsParticipants37,673 participants\
80 contiguous geographic clusters (40 clusters in each study group)\
Inclusion criteria: 24 months of age and older, no reported fever or had an axillary temperature not greater than 37.5°C at time of administration\
Exclusion criteria: not statedInterventionsSingle‐dose capsular polysaccharide of *S.* Typhi, Vi vaccine (dose 25 mcg)Inactivated hepatitis A vaccine (dose 720 IU for children 2 to 18, 1440 IU for adults)\
Route and schedule: single intramuscular injection, Vi vaccine or inactivated hepatitis A vaccineOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Indirect protection from typhoid feverAdverse eventsNotesLocation: Kolkata, India\
Socioeconomic description: slum‐dwelling residents\
The clusters were stratified according to ward and the number of residents who were 18 years of age or younger (\< 200 versus ≥ 200 people) and the number of residents who were older than 18 years (\< 500 versus ≥ 500 people), resulting in 8 strata\
Date: November 2004 to December 2006\
Setting: vaccination centres set up for each cluster and health clinics***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Used a table of random numbers to assign half the 80 clusters to each vaccine\"Allocation concealment (selection bias)Low risk\"The vaccines were labelled only with code letters.\" However, 2 vaccines were not packaged in an identical fashion. Attempts to minimize this bias unlikely to have affected the findings of the trialBlinding (performance bias and detection bias) All outcomesLow riskParticipants and study personnel blind. Not stated whether outcome assessors were blindedIncomplete outcome data (attrition bias) All outcomesLow riskReasons for missing data given (migration, dying from other causes) and balanced across groupsSelective reporting (reporting bias)Low riskStudy protocol not available but published study reports on both primary and secondary outcomesOther biasLow riskNo recruitment bias, no baseline imbalance, no loss of clusters, analysis adjusted for clustering using generalized estimating equation[@CD001261-bbs2-0022]MethodsDesign: cluster‐RCT (classroom)\
Intermediate surveillance for efficacy: isolation of *S.* Typhi from blood in the hospital during the study (3 years)\
Surveillance for adverse events: no detailsParticipantsNumber: 32,388\
Inclusion criteria: age 6 to 7 years; no further details\
Exclusion criteria: no detailsInterventionsLiquid formulation of *S.* Typhi, Ty21a: 16,486 participantsPlacebo: 15,902 participants\
Route and schedule: oral solution; 3 doses, alternate days\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Adverse eventsNotesLocation: Alexandria, Egypt\
Socioeconomic description: no details\
Setting: school\
Date: 1978 to 1981\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Unclear riskVaccine and placebo identical. Allocation concealment unclearBlinding (performance bias and detection bias) All outcomesLow riskVaccine and placebo identicalIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomly assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll expected outcomes reported onOther biasUnclear riskAnalysis not adjustment for clustering[@CD001261-bbs2-0023]MethodsDesign: cluster‐RCT (classroom)\
Surveillance for adverse events: no detailsParticipantsNumber: 884\
Inclusion criteria: age 6 to 7 years; no further details\
Exclusion criteria: no details\
This trial was a pilot study done prior to [@CD001261-bbs2-0022] (see above) to assess tolerability of the vaccines. Results were presented as part of the trial data for [@CD001261-bbs2-0022].InterventionsLiquid formulation of *S.* Typhi, Ty21a: 413 participantsPlacebo: 471 participants\
Route and schedule: oral solution; 3 doses, alternate days\
Concomitant medication: not specifiedOutcomesAdverse eventsNotesLocation: Alexandria, Egypt\
Socioeconomic description: no details\
Setting: school\
Date: 1978\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskGeneration of allocation sequence: unclearAllocation concealment (selection bias)Unclear riskVaccine and placebo identical. Allocation concealment unclearBlinding (performance bias and detection bias) All outcomesLow riskVaccine and placebo identicalIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomly assigned participants in analysis: 100%Selective reporting (reporting bias)Unclear riskAll expected outcomes reported onOther biasUnclear riskAnalysis not adjusted for clustering[@CD001261-bbs2-0024]MethodsDesign: individually based RCT\
Passive surveillance for efficacy: signs and symptoms of typhoid fever; blood cultures and serum Widal\'s test (1 year)ParticipantsNumber: 81,506\
Inclusion criteria: age 5 to 55 years; healthy\
Exclusion criteria: history of liver, kidney or heart disease; hypertension; acute infection; psychiatric disease; allergic history; prior typhoid infection; pregnancy; prior typhoid vaccination in the last 2 yearsInterventionsCapsular polysaccharide of *S.* Typhi, Vi vaccine: 30 µg Vi: 41,118 participantsMeningococcal vaccine: 40,388 participants\
Route and schedule: intramuscular injection; 1 dose\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Adverse reactions\
Subgroups for age and genderNotesLocation: Baoying County, Jiangsu Province, China\
Socioeconomic description: no details\
Setting: no details\
Date: 1994 to 1995\
No demographic information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskGeneration of allocation sequence: computer‐generated random numbersAllocation concealment (selection bias)Low riskAllocation concealment: code concealed from field workers and study populationBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind. Identical vaccine and placebo vialsIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data. Inclusion of randomly assigned participants in analysis: 100%Selective reporting (reporting bias)Low riskAll expected outcomes reported onOther biasLow riskNone[@CD001261-bbs2-0025]MethodsDesign: individually based RCT\
Passive surveillance for efficacy: clinical symptoms; positive blood cultures and serum Widal\'s test during trial (1.6 years)\
Surveillance for adverse events: parental reporting of adverse effects in 3 schoolsParticipantsNumber: 131,271\
Inclusion criteria: healthy children aged 3 to 19 years and adults aged \< 51 years\
Exclusion criteria: chronic disease; under medication; pregnancyInterventionsCapsular polysaccharide of *S.* Typhi, Vi vaccine: 30 µg Vi; 65,287 participantsPlacebo: 65,984 participants\
Route and schedule: hypodermically; 1 dose\
Concomitant medication: not specifiedOutcomesTyphoid fever cases (*S.* Typhi bacteraemia)Adverse events\
Subgroups for age, profession and sexNotesLocation: county of Quan, north‐eastern part of Guangxi Zhuang\
Autonomous Region, southern China\
Socioeconomic description: no details\
Setting: clinic\
Date: 1995 to 1996\
Age, sex and profession similar in both groups***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskGeneration of allocation sequence: unique serial number to each participant; having an even or an odd number determined allocation to vaccine or placeboAllocation concealment (selection bias)Low riskAllocation concealment: code concealed from field workers and study populationBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blindIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome dataSelective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasLow riskNone[@CD001261-bbs2-0026]MethodsDesign: individually based RCT\
Active surveillance for adverse events: all participants were observed for 2 hours at the vaccination site after administration of the study agent and were visited by trained clinicians on days 1, 2, 3 and 28ParticipantsNumber: 667\
Inclusion criteria: school children aged 9 to 14 who have previously received a primary dose of Vi vaccine, no signs or symptoms consistent with an infection within the 2 weeks before injection, no history of typhoid fever and axillary temperature of 37.5°C on the day of the planned injection\
Exclusion criteria: no previous primary dose of Vi vaccine, signs or symptoms of infection within the 2 weeks before injection, history of typhoid fever or axillary temperature higher than 37.5°C on day of planned injectionInterventionsCapsular polysaccharide of *S.* Typhi, Vi vaccine to previously vaccinated children (revaccination), 334 participantsPlacebo (normal saline), 333 participants\
Route and schedule: intramuscular injection, one doseOutcomesAdverse eventsNotesLocation: Suzhou, Jiangsu, China\
Socioecomic description: no details\
Setting: school\
Date: 2002***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Computer generated random numbers\"Allocation concealment (selection bias)Unclear riskInsufficient information to permit judgementBlinding (performance bias and detection bias) All outcomesLow riskDouble‐blind -- blinding of participants and study personnel. Vaccine and placebo identicalIncomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome dataSelective reporting (reporting bias)Low riskAll expected outcomes reportedOther biasLow riskNone[^10]

Characteristics of excluded studies \[ordered by study ID\] {#CD001261-sec2-0020}
===========================================================

StudyReason for exclusion[@CD001261-bbs2-0027]No relevant outcome measures[@CD001261-bbs2-0028]Letter; not an RCT[@CD001261-bbs2-0029]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0030]No efficacy data yet for Vi‐CRM197 so according to protocol cannot include for side effects/safety only[@CD001261-bbs2-0031]No relevant outcome measures[@CD001261-bbs2-0032]Additional info for [@CD001261-bbs2-0039] ‐ human challenge study -- already excluded[@CD001261-bbs2-0033]Evaluated experimental live‐attenuated oral vaccine candidates; no efficacy trials of this vaccine[@CD001261-bbs2-0034]Study arms randomly assigned to receive different doses of same vaccine[@CD001261-bbs2-0035]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0036]Compared 2 Vi polysaccharide vaccines made by 2 different companies[@CD001261-bbs2-0037]No relevant control group[@CD001261-bbs2-0038]Evaluated Vi vaccine versus inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0039]Human challenge study[@CD001261-bbs2-0040]RCT compared different doses of the Ty21a vaccine[@CD001261-bbs2-0041]Two separate randomized trials, described together; none of the chemical subunit vaccines that were studied are in use[@CD001261-bbs2-0042]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0043]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0044]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0045]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0046]Evaluated adverse events of new M01ZH09 vaccine, no efficacy trials of this vaccine[@CD001261-bbs2-0047]No random allocation[@CD001261-bbs2-0048]No random allocation[@CD001261-bbs2-0049]Vi‐CRM197 human challenge study. Published protocol and note on register that ended prematurely[@CD001261-bbs2-0050]Vi‐TT (Typbar‐TCV) ‐ human challenge study ‐ excluded[@CD001261-bbs2-0051]Additional information on [@CD001261-bbs2-0039] -- excluded as human challenge study[@CD001261-bbs2-0052]No relevant outcome measures[@CD001261-bbs2-0053]No relevant outcome measures[@CD001261-bbs2-0054]Non‐randomized study[@CD001261-bbs2-0055]Evaluated safety of Vi vaccine compared with meningococcal vaccine or combination[@CD001261-bbs2-0056]Evaluated adverse events of new M01ZH09 vaccine; no efficacy trials of this vaccine[@CD001261-bbs2-0057]Evaluated different brands of Vi vaccine[@CD001261-bbs2-0058]No random allocation; compared Vi with inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0059]Evaluated adverse events of new M01ZH09 vaccine; no efficacy trials of this vaccine[@CD001261-bbs2-0060]Review article ‐ no new trials referenced[@CD001261-bbs2-0061]No efficacy data for Typbar TCV yet so excluded as per protocol as must have efficacy data available for vaccine for adverse effects to be included in review[@CD001261-bbs2-0062]No random allocation to vaccine and placebo arms[@CD001261-bbs2-0063]No random allocation[@CD001261-bbs2-0064]No efficacy or adverse effects/safety outcomes[@CD001261-bbs2-0065]Compared Vi vaccine with inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0066]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0067]Compared 2 brands of Vi vaccine[@CD001261-bbs2-0068]Evaluated experimental live‐attenuated oral vaccine candidates; no efficacy trials of these vaccines[@CD001261-bbs2-0069]Evaluated experimental live‐attenuated oral vaccine candidates; no efficacy trials of these vaccines[@CD001261-bbs2-0070]Evaluated experimental live‐attenuated oral vaccine candidates; no efficacy trials of these vaccines[@CD001261-bbs2-0071]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0072]No relevant outcome measures[@CD001261-bbs2-0073]Adverse event only trial and placebo not used for comparison (Hibb vaccine used as comparison)[@CD001261-bbs2-0074]Evaluated adverse events of new conjugate vaccine (Vi‐CRM); no efficacy trials of this vaccine[@CD001261-bbs2-0075]Additional data for Mohan 2015 ‐ Vi‐TT (Typbar‐TCV) ‐ no efficacy data, immunological data[@CD001261-bbs2-0076]Quasi‐RCT evaluating the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0077]No relevant outcome measures[@CD001261-bbs2-0078]No relevant outcome measures[@CD001261-bbs2-0079]Safety only, evaluated different brands of same vaccine[@CD001261-bbs2-0080]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0081]Evaluated the inactivated whole‐cell vaccine, which is no longer in use[@CD001261-bbs2-0082]Safety only; evaluated different brands of same vaccine[^11]

Characteristics of ongoing studies \[ordered by study ID\] {#CD001261-sec2-0021}
==========================================================

[@CD001261-bbs2-0083]Trial name or titleAssessing the impact of a Vi‐polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children -- a phase IV trialMethodsCluster‐randomized controlled trialParticipantsConsenting children/guardians within the age range (9 months to \< 16 years) residing in the area of Mirpur, Dhaka\
Inclusion criteria:\
Parent/guardian is willing and competent to provide informed consent. If the participant is 11 to \< 16 years of age, informed assent will also be soughtAged between 9 months (or eligible for measles vaccination according to local protocol) and \<16 years (that is, up to 15 years 364 days) at time of vaccinationApparently healthy (no complaints of febrile illness) on the day of vaccinationParent/guardian confirms that their child will be willing and be able to comply with study requirements including follow‐up contact, according to the scheduleLiving within the study catchment area at the time of vaccination\
Exclusion criteria:\
Has knowingly received a typhoid or Japanese encephalitis vaccine in the last three yearsKnown allergy to any of the vaccine componentsMedical or social reasons that will prevent the participant from conforming to the study requirements as judged by a medical professionalPlanning to move away from the catchment area within the next monthPregnant at the time of vaccination, as confirmed by a urine test (urine pregnancy test will be done in girls who are married)\
Target number of participants: 43,350\
150 Residential clusters of around 1250 people each are randomized in a 1:1 ratio to receive Vi‐TCV or the control vaccine (SA 14‐14‐2).InterventionsIntervention: Vi Typhoid conjugate vaccine (Vi‐TCV), trade name: TyBar Control: Japanese encephalitis vaccine: trade name: SA14‐14‐2, Japanese encephalitis vaccine, LiveOutcomesPrimary outcome: the efficacy and rate reduction of the Vi‐TCV in preventing blood culture‐confirmed symptomatic infection caused by *S.* Typhi, measured through the incidence of blood culture confirmed typhoid fever in vaccinees in intervention clusters compared to control clusters\
Secondary outcomes: Vi‐TCV safety, efficacy and rate reduction of typhoid fever in clusters, impact on fever presentation, impact on clinical diagnosis typhoid fever, paratyphoid fever infection ratesStarting date12 February 18Contact informationProf Andrew Pollard,\
Oxford Vaccine Group\
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)\
Churchill Hospital Old Road\
Oxford\
OX3 7LE\
United KingdomNotesA pilot phase, prior to the main study, individually randomises 200 children, in an area separate from the main trial site, in an age stratified manner to receive either Vi‐TCV or the JE vaccine. Safety data is presented to the local DSMB (LDSMB), IRB and to the Directorate General of Drug Administration (DGDA), the National Regulatory Authority of Bangladesh prior to initiating the main cluster‐randomized trial\
Intention to publish date: 1 February 2021\
Trial protocol available: [www.isrctn.com/ISRCTN11643110](www.isrctn.com/ISRCTN11643110)[@CD001261-bbs2-0084]Trial name or titleAssessing the impact of a Vi‐polysaccharide conjugate vaccine in preventing typhoid infection among Nepalese children -- a phase III trialMethodsRandomized controlled trialParticipantsInclusion criteria\
Parent/legal guardian is willing and competent to provide informed consent. If the participant is 12 years of age or older, informed assent will also be soughtAged between 9 months (or eligible for measles vaccination according to local protocol) and \< 16 years (that is, up to 15 years 364 days) at time of vaccinationIn good health on the day of vaccinationParent/legal guardian confirms that their child will be wiling and be able to comply with study requirements including follow‐up contact, according the trial scheduleLive within the study catchment area at the time of vaccination\
Exclusion criteria\
Parent/legal guardian is willing and competent to provide informed consent. If the participant is 12 years of age or older, informed assent will also be soughtAged between 9 months (or eligible for measles vaccination according to local protocol) and \< 16 years (that is, up to 15 years 364 days) at time of vaccinationIn good health on the day of vaccinationParent/legal guardian confirms that their child will be wiling and be able to comply with study requirements including follow‐up contact, according the trial scheduleLive within the study catchment area at the time of vaccination\
Target number of participants: 20,000InterventionsIntervention: Vi Typhoid conjugate vaccine (Vi‐TCV), trade name: TyBar, single dose\
Control: meningococcal group A vaccine (MenA), trade name: MenAfriVac, single doseOutcomesPrimary outcome: efficacy and rate reduction of Vi‐TCV in preventing blood culture confirmed *S.* Typhi infection\
Secondary outcomes: safety of Vi‐TCV, impact on admission rates for febrile illness days spent in hospital with febrile illness, incidence of clinically suspected typhoid fever, paratyphoid infection rates\
Follow‐up: 2 yearsStarting date1 November 2017Contact informationProf Andrew Pollard\
Oxford Vaccine Group\
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)\
Churchill Hospital Old Road\
Oxford\
OX3 7LE\
United KingdomNotesIntention to publish date: 1 August 2021\
Trial protocol: [www.isrctn.com/ISRCTN43385161](www.isrctn.com/ISRCTN43385161)[@CD001261-bbs2-0085]Trial name or titleA phase III randomized, double‐blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine (Vi‐TCV) among children age 9 months through 12 years in Blantyre, MalawiMethodsRandomized controlled trial\
(Participant, investigator, outcomes assessor blinded)ParticipantsInclusion criteria\
Healthy male or female child between the ages of 9 months and 12 years/364 days at the time of study vaccinationA child whose parent or guardian resides primarily within the Ndirande or Zingwangwa study areas at the time of study vaccinations and who intends to be present in the area for the duration of the trialA child whose parent or guardian has voluntarily given informed consent\
Exclusion criteria\
History of documented hypersensitivity to any component of the vaccinePrior receipt of any typhoid vaccine in the past 3 yearsHistory of severe allergic reaction with generalized urticarial, angioedema, or anaphylaxisAny condition determined by the investigator to be likely to interfere with evaluation of the vaccine or to be a significant potential health risk to the child or make it unlikely that the child would complete the study\
Target number of participants: 24,000InterventionsIntervention: Vi‐typhoid conjugate vaccine (Vi‐TCV); single 0.5‐mL intramuscular injection\
Control: meningococcal A conjugate vaccine (MCV‐A); single intramuscular injection. Children 9‐11 months will receive a 5 µg/0.5 mL dose. Children 12 months and older will receive a 10 µg/0.5 mL doseOutcomesPrimary outcome: efficacy of Vi‐TCV (blood culture confirmed; follow‐up until 36 months)\
Secondary outcomes: safety of Vi‐TCV (follow‐up until 6 months); immunogenicity of Vi‐TCV (28 days); number of typhoid fever cases prevented by Vi‐TCV (follow‐up until 36 months)Starting dateJanuary 2018Contact informationPrincipal Investigator: Kathleen Neuzil, Professor, University of Maryland\
Provided contact details: Kenneth Simiyu [Ksimiyu\@som.umaryland.edu](Ksimiyu@som.umaryland.edu); Ian Woods [iwoods\@som.umaryland.edu](iwoods@som.umaryland.edu)NotesEstimated study completion date: January 2021\
Trial protocol: [clinicaltrials.gov/show/NCT03299426](clinicaltrials.gov/show/NCT03299426)

RM: data collection and management, analysis, interpretation of results, and review writing. AN: data collection, analysis, and review writing. MR: data analysis, review writing. MP: data analysis, review writing. All review authors read and approved the final manuscript.
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^a^No serious risk of bias detected. ^b^No serious indirectness detected: studies based in Chile, Indonesia, and Egypt. ^c^No serious inconsistency I^2^ = 33%. ^d^Downgraded for imprecision: cluster‐adjusted trials added, estimated ICC = 0.0015 (from [@CD001261-bbs2-0021]). ^e^No serious inconsistency, no heterogeneity I^2^ = 0%. ^f^There is moderate heterogeneity (I^2^ = 50%), which is not explained by stratifying into type of preparation. However, the CIs fall within a clinically important threshold, meaning the heterogeneity is unlikely be clinically significant, so we have not downgraded for this.

[^3]: ^a^The incidence of typhoid in a medium‐risk setting is taken from the control group in a study from China ([@CD001261-bbs2-0025]).The incidence of typhoid in a high‐risk setting is taken from a study in India ([@CD001261-bbs2-0021]). This is consistent with the incidence levels described by a global epidemiological study ([@CD001261-bbs2-0091]). ^b^No serious risk of bias detected. ^c^No serious inconsistency: The result was consistent across all 3 trials (I^2^ = 0%). ^d^No serious indirectness: the vaccine has been evaluated in trials from Nepal, South Africa and China. Of note, none of the trials were conducted in travellers from nonendemic settings, and all three trials excluded children younger than 2 years of age and pregnant women. ^e^No serious imprecision: the result is statistically significant with a narrow 95% CI. The meta‐analysis is adequately powered to detect this effect. ^f^Downgraded by 1 level for inconsistency: the magnitude of the protective effect varied between trials from 34% to 69% (I^2^ = 72%). The reasons for this are not clear; one potential factor may be the different age groups included in the trials, with [@CD001261-bbs2-0006] suggesting lower protective effect in children \< 5 years of age. ^g^No serious indirectness: the vaccine has been evaluated in trials from endemic settings (India, Pakistan, China and South Africa). ^h^Downgraded by 1 level for imprecision: wide CIs. ^i^Downgraded by 1 level for indirectness ‐ only assessed in one trial in South Africa in children aged 5 to 15 years. ^k^No serious indirectness: the vaccine has been evaluated in trials from endemic settings (China) and in one trial conducted in a non‐endemic setting (USA). ^l^Downgraded by 1 level for serious imprecision: The result is not statistically significant. ^j^Downgraded by 1 level for inconsistency (I^2^ = 63%).

[^4]: ^a^The incidence of typhoid in a medium‐risk setting is taken from the control group in a study from China ([@CD001261-bbs2-0025]). The incidence of typhoid in a high‐risk setting is taken from a study in India ([@CD001261-bbs2-0021]). This is consistent with the incidence levels described by a global epidemiological study ([@CD001261-bbs2-0091]). ^b^No serious risk of bias detected. ^c^Downgraded by 1 level for indirectness: the vaccine has been evaluated by only one trial in children 2 to 5 years of age in a high‐incidence setting (Vietnam). ^d^Downgraded by 1 level for imprecision: wide 95% CIs. ^e^Downgraded by 1 level for serious imprecision: the result is not statistically significant.

[^5]: ^a^The basis for the assumed risk is taken from the disease incidence in the control group in the trial ([@CD001261-bbs2-0017]). ^b^Primary trial is not cluster‐adjusted. This estimate uses a small assumed intracluster correlation coefficient of 0.0015 calculated from cluster‐randomized ViPs vaccine trial [@CD001261-bbs2-0021], which did adjust for clustering. ^c^Downgraded by 1 level for risk of bias. ^d^Downgraded by 1 level for imprecision. Wide CIs that include appreciable harm and few (11 events) in the trial. ^e^Downgraded by 1 level for indirectness. Only one trial in one setting and in children under 12 years.

[^6]: Abbreviations: CI: confidence interval; ICC: intracluster correlation coefficient. ^a^ICC calculated from [@CD001261-bbs2-0021]. ^b^Average cluster size for [@CD001261-bbs2-0022] calculated using pilot trial cluster size information.

[^7]: Abbreviations: RR: risk ratio; CI: confidence interval. ^a^Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect. ^b^Risk ratio with 95% CIs. ^c^Efficacy = 1 − risk ratio.

[^8]: ^a^Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.

[^9]: Abbreviations: CI: confidence interval.

[^10]: **Cluster‐RCT**: randomized controlled trial that randomly assigned clusters (for example, classrooms); **ELISA**: enzyme‐linked immunosorbent assay; **individually‐based RCT**: randomized controlled trial that randomly assigned individual participants; **WHO**: World Health Organization.

[^11]: **RCT**: randomized controlled trial.
